Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 1    Clinical Study Protocol  
 Drug Substance  Durvalumab  
 Study Code  D910FC00001  
 Version  4.0  
 Date  12 April 2022  
 
 
 An Open -Label, Multi -Center, Global Study to Evaluate Long Term Safety 
and Efficacy in Patients Who are Receiving or Who Previously Received 
Durvalumab in Other Protocols (WAVE)  
   
Sponsor:  AstraZeneca AB, 151 85 Södertälje, Sweden  
 
Regulatory Agency Identifying Number(s):  EudraCT 2019-001402-20; IND 143828 
 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 5  TABLE OF CONTENTS  
VERSION HISTORY  ............................................................................................. 2 
TABLE OF CONTENTS ........................................................................................ 5  
1. PROTOCOL SUMMARY  .................................................................................... 11 
1.1 Schedule of activities ............................................................................................. 12 
1.2 Synopsis ................................................................................................................. 22 
1.3 Schema  .................................................................................................................. 26 
2. INTRODUCTION  ................................................................................................. 27 
2.1 Study rationale  ....................................................................................................... 27 
2.2 Background ........................................................................................................... 27 
2.2.1  Immunotherapies  ................................................................................................... 27 
2.2.2  Durvalumab  ........................................................................................................... 28 
2.3 Benefit/risk assessment  ......................................................................................... 30 
2.3.1  Overall benefits  ..................................................................................................... 30 
2.3.1.1  Benefits of durvalumab as monotherapy ............................................................... 30 
2.3.2  Overall risks  .......................................................................................................... 30 
2.3.2.1  Potential risks of durvalumab monotherapy  .......................................................... 31 
3. OBJECTIVES AND ENDPOINTS ....................................................................... 32 
4. STUDY DESIGN  .................................................................................................. 32 
4.1 Overall design ........................................................................................................ 32 
4.2 Scientific rationale for study design  ...................................................................... 33 
4.2.1  Rationale for retreatment option ............................................................................ 33 
4.3 Justification for dose  ............................................................................................. 33 
4.3.1  Durvalumab dose and treatment regimen justification  .......................................... 33 
4.3.1.1  Durvalumab monotherapy dose rationale  .............................................................. 33 
4.3.1.2  Rationale for fixed dosing  ..................................................................................... 34 
4.3.1.3  Rationale for duration of treatment  ....................................................................... 35 
4.4 End of study definition  .......................................................................................... 35 
5. STUDY POPULATION ........................................................................................ 35 
5.1 Inclusion criteria  .................................................................................................... 36 
5.2 Exclusion criteria  ................................................................................................... 38 
5.3 Lifestyle restrictions  .............................................................................................. 41 
5.4 Screen failures  ....................................................................................................... 43 
6. STUDY TREATMENTS ...................................................................................... 43 
6.1 Treatments administered  ....................................................................................... 43 
6.1.1  Investigational product  .......................................................................................... 43 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 6   6.1.1.1  Durvalumab (MEDI4736)  ..................................................................................... 44 
6.1.2  Dose and treatment regimen  .................................................................................. 45 
6.1.2.1  Durvalumab (MEDI4736) monotherapy ............................................................... 45 
6.1.3  Duration of treatment and criteria for treatment through progression and for 
retreatment  ............................................................................................................. 46 
6.1.4  Storage  ................................................................................................................... 47 
6.2 Measures to minimize bias: randomization and blinding  ...................................... 47 
6.3 Treatment compliance  ........................................................................................... 48 
6.4 Concomitant therapy  ............................................................................................. 48 
6.4.1  Other concomitant treatment  ................................................................................. 50 
6.4.2  Durvalumab drug- drug interactions  ...................................................................... 50 
6.4.3  Rescue medication  ................................................................................................. 50 
6.5 Dose modification  ................................................................................................. 51 
6.6 Treatment after the end of the study  ...................................................................... 51 
7. DISCONTINUATION OF TREATMENT AND PATIENT WITHDRAWAL  .. 52 
7.1 Discontinuation of study treatment  ....................................................................... 52 
7.1.1  Procedures for discontinuation of study treatment  ................................................ 52 
7.2 Lost to follow -up ................................................................................................... 53 
7.3 Withdrawal from the study  .................................................................................... 54 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................................ 54 
8.1 Safety assessments  ................................................................................................ 55 
8.1.1  Clinical safety laboratory assessments  .................................................................. 56 
8.1.2  Physical examinations  ........................................................................................... 57 
8.1.3  Vital signs  .............................................................................................................. 58 
8.1.4  Early patient review for safety for retreated patients  ............................................ 58 
8.1.5  WHO/ECOG performance status  .......................................................................... 59 
8.1.6  Other safety assessments  ....................................................................................... 59 
8.2 Efficacy assessments  ............................................................................................. 60 
8.2.1  Parent study assessments  ....................................................................................... 60 
8.2.2  Survival assessments  ............................................................................................. 61 
8.2.3  Clinical endpoint assessments  ............................................................................... 61 
8.3 Collection of adverse events  .................................................................................. 62 
8.3.1  Method of detecting AEs and SAEs  ...................................................................... 62 
8.3.2  Time period and frequency for collecting AE and SAE information  .................... 62 
8.3.3  Follow-up of AEs and SAEs  ................................................................................. 63 
8.3.4  Adverse event data collection  ................................................................................ 63 
8.3.5  Causality collection  ............................................................................................... 64 
8.3.6  Adverse events based on signs and symptoms  ...................................................... 64 
8.3.7  Adverse events based on examinations and tests  .................................................. 65 
8.3.8  Hy’s law  ................................................................................................................ 65 
8.3.9  Disease under study  ............................................................................................... 65 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 7   8.3.10  Disease progression  ............................................................................................... 65 
8.3.11  New cancers .......................................................................................................... 66 
8.3.12  Deaths  .................................................................................................................... 66 
8.3.13  Adverse events of special interest  ......................................................................... 66 
8.3.14  Safety data to be collected following the final DCO of the study ......................... 68 
8.4 Safety reporting and medica l management  ........................................................... 68 
8.4.1  Reporting of serious adverse events  ...................................................................... 68 
8.4.2  Pregnancy  .............................................................................................................. 69 
8.4.2.1  Maternal exposure  ................................................................................................. 69 
8.4.2.2  Paternal exposure  .................................................................................................. 69 
8.4.3  Overdose  ................................................................................................................ 70 
8.4.3.1  Durvalumab  ........................................................................................................... 70 
8.4.4  Management of durvalumab- related toxicities  ...................................................... 70 
8.4.4.1  Specific toxicity management and dose modification information – 
Durvalumab  ........................................................................................................... 71 
8.5 Pharmacokinetics  ................................................................................................... 72 
8.6 Pharmacodynamics  ................................................................................................ 72 
8.7 Genetics  ................................................................................................................. 72 
8.8 Biomarkers  ............................................................................................................ 72 
9. STATISTICAL CONSIDERATIONS .................................................................. 72 
9.1 Sample size determination ..................................................................................... 72 
9.2 Populations for analyses  ........................................................................................ 72 
9.3 Statistical analyses  ................................................................................................. 73 
9.3.1  Safety analyses  ...................................................................................................... 73 
9.3.2  Efficacy analyses  ................................................................................................... 73 
9.3.3  Endpoint measures for analyses  ............................................................................ 73 
9.3.3.1  Calculation or derivation of safety variables  ......................................................... 73 
9.3.3.2  Investigator RECIST 1.1 -based assessments  ........................................................ 74 
9.3.3.3  Objective response rate  ......................................................................................... 74 
9.3.3.4  Duration of response  ............................................................................................. 74 
9.3.3.5  Overall survival  ..................................................................................................... 74 
9.4 Interim analyses  ..................................................................................................... 74 
9.4.1  Data monitoring committee  ................................................................................... 75 
10. REFERENCES ...................................................................................................... 76 
11. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ............................................................................................ 79
 
11.1  Study management  ................................................................................................ 79 
11.1.1  Data entry/electronic data capture  ......................................................................... 79 
11.1.2  Source documents .................................................................................................. 79 
11.1.3  File retention and archiving  ................................................................................... 79 
11.1.4  Quality assurance and monitoring  ......................................................................... 80 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 8   11.1.5  Data management  .................................................................................................. 80 
11.1.6  Changes to the protocol  ......................................................................................... 80 
11.1.7  Publication policy  .................................................................................................. 81 
12. ETHICAL AND REGULATORY CONSIDERATIONS  .................................... 81 
12.1  Guiding principles  ................................................................................................. 81 
12.2  Required documents  .............................................................................................. 81 
12.3  Financial disclosure  ............................................................................................... 82 
12.4  Patient information and informed consent  ............................................................ 82 
12.5  Patient confidentiality  ............................................................................................ 82 
12.6  Independent ethics committee (IEC)/institutional review board (IRB) ................ 83 
 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 9  LIST OF TABLES  
Table  1 Schedule of assessments for patients currently receiving treatment with 
durvalumab monotherapy (Cohort  1) .................................................................. 14  
Table  2 Schedule of assessments for patients who completed treatment with 
durvalumab monotherapy or durvalumab in combination with any other 
approved or investigational anticancer agents, and are eligible for future 
retreatment (Cohort 2)  ......................................................................................... 17  
Table  3 Schedule of assessments for patients who previously received treatment with 
durvalumab monotherapy or durvalumab in combination with any other approved or investigational anticancer agents, and are not eligible for any future treatment (Cohort 3)  .................................................................................. 20
 
Table 4  Study objectives ................................................................................................... 32  
Table 5  Highly effective methods of contraception (<1% failure rate)  ............................. 42  
Table 6  Study treatment ..................................................................................................... 44  
Table 7  Prohibited concomitant medications  .................................................................... 49  
Table 8  Supportive medications  ........................................................................................ 50  
Table 9  Clinical chemistry  ................................................................................................. 56  
Table 10  Hematology .......................................................................................................... 57  
Table 11  Population for statistical analyses  ........................................................................ 72  
Table 12  Summary of imaging modalities for tumor assessment  ....................................... 94  
Table 13  Evaluation of target lesions  .................................................................................. 98  
Table 14  Evaluation of non- target lesions  ........................................................................... 99  
Table 15  Overall visit response  ......................................................................................... 100  
 
LIST OF FIGURES  
Figure 1  Study design ......................................................................................................... 26  
Figure 2  Durvalumab monotherapy dosing schedule ......................................................... 46  
  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001   
CONFIDENTIAL AND PROPRIETARY 10  LIST OF APPENDICES  
Appendix  A Adverse Even t Definitions and Additional Safety Information  ................... 84 
Appendix  B Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law  ....................................................................................... 88 
Appendix  C Guidelines for Evaluation of Objective Tumor Response Using RECIST 
1.1 Criteria (Response Evaluation Criteria in Solid Tumors)  .............................. 93 
Appendix  D Abbreviations  .............................................................................................. 104 
 
 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 11 1. PROTOCOL SUMMARY
This is a multicenter, open- label study  that will enroll patients w ho are currently r eceiving  
durvalumab or have previously received durvalumab as monotherapy or in combination with 
other ag ents in an el igible AstraZeneca/MedImmune -sponsored clinical study (herei n referre d to 
as a parent clinical study). The aims of the study are to monitor the long- term safety o f 
durvalumab,  to pr ovide c ontinued treatment or  retreatment with dur valumab to e ligible patients, 
and to collect overall surviva l (OS) information.  
Patients in this s tudy will be e nrolled in to on e of 3 Cohorts: 
Cohort 1 includes patients who received durvalumab monotherapy or durvalumab combination 
therapy under the parent clinical study (includi ng those unde rgoing retreatment per the parent 
study) who have not clinically progressed a nd who are eligible to continue dur valumab treatment 
after completing  dosing of all other anticancer agents, in cluding  other investigationa l agents , 
which are a formal co mponent of  the parent study. If a patient w as already retreated with 
durvalumab in the parent clinical study and has not progresse d while on treatment, then they 
would be  potentially e ligible to e nter Cohort 1; a combination  treatment course in itiated in the  
parent  clinical study  must be  completed pr ior to study entry. All treatment cycle assessments will 
occur  every 4 w eeks (±3 da ys) unt il confirmed p rogressive di sease (PD), unless unacceptable 
toxicity, withdrawal of consent, or another discontinuation criterion is met. Treatment beyond 
disease progression  is allowed at the  Investigator’s di scretion,  if it is in the  patient’s b est interest. 
The baseline  imaging results f rom start of  the parent clinical study  will be used for  baseline  
tumor assessments for Cohort 1. Follow- up tumor asses sments will be  performed according to 
the Investigator’s standard practice using  Response Evaluation Criteria in Solid Tumors version 
1.1 (RECIST v1.1; at least every 12 weeks) (Table 1). Upon discontinuation of durvalumab, 
patients may r eceive any  subsequent  anticancer therapy  at the discretion  of the Investigator and  
will follow the schedule of activities (SoA) detailed for Cohort 3 for safety and survival follow-
up (Table 3).  
Cohort 2 includes patients who completed durvalumab monotherapy or in combinati on with any 
other approved or investigational anticancer agents in a parent study, without confirmed PD 
during  the period  of treatment, a nd who  are pot entially e ligible for  retreatment with durvalumab.  
The patient should not have received any other approved or investigational anticancer agents 
since c ompletion  of durvalumab treatment. Patients w ho completed the prespecified duration of 
treatment with dur valumab in a pa rent clinical study,  who re ceived c linical bene fit and the n 
subsequently experienced confirme d PD after completion of planned treatment, will be permitted 
to restart durvalumab treatment provided the y meet the  eligibility criteria. If a pa tient was 
already retreated with durvalumab i n the parent clinical study and retreatment has ended, they 
are no  long er eligible for  retreatmen t in thi s study. In addition, interveni ng chemotherapy 
treatment will not be a llowed be fore r etreatment  with dur valumab.  Cohort 2 pa tients w ho will be  
eligible for future retreatment with durvalumab must agree to reconsenting to start retreatment 
and meet the eligibility criteria detailed  in Sections 5.1 and 5.2. Patients who undergo 
retreatment  will follow  assessments a s per the SoA for  Cohort 1 unt il confirmed P D, unl ess 
unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met 
(Table 2). Only 1 course of retreatment is allowed (inclusive of any retreatment in the parent 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 12 clinical study). Treatment  beyond  disease progression  is allowed at the  Investigator’s discretion,  
if it is in the  patient’s b est interest. T he ba seline  imaging results fo r Cohort 2 mus t be a vailable 
within 28 da ys of retreatment. W hile on  retreatment, fo llow-up tumor assessments will be  
performed according to the Investigator’s standard practice (at least ev ery 12 weeks) using 
RECIST v1.1 (Table 1). Upon discontinuation of durvalumab, patients may receive any 
subsequent anticancer therapy at the discretion of the Investigator and will follow the SoA 
detailed for Cohort 3 for safety and survival follow-up ( Table 3).   
Cohort 3 inc ludes s urvival follow -up only for patients previously treate d with durvalumab 
monotherapy or durvalumab in combination with any other approved or investigational 
anticancer agents who are no longer receiving durvaluma b and are not eligible to receive 
retreatment. Safety as sessments will be collected among  the patients who  are within 9 0 days 
since last dose of study drug in the parent study. The patients would undergo OS assessments as 
per the SoA (Table 3) and may receive any subsequent anticancer therapy at the discretion of the 
Investigator.  
For all cohorts, any a ssessments which ar e relevant  to preservation  of patient safety, as scheduled 
in the parent clinical study, will be conducted and followed up as per the SoA for this study. 
1.1 Schedule of activities  
The SoA are based on Cohort entry type as part of the study design ( Table 1 to Table 3 ).  
Patients in Cohort 1 a nd those going onto durvalumab retreatment in Cohort 2 will receive 
durvalumab monotherapy by infusion every 4 weeks on Day 1 of each cycle. F or all patients 
treated w ith durvalumab,  cycle assessments will b e completed every 4 w eeks ( ±3 days) until 
confirmed PD, unless unacceptable toxicity, withdrawal of consent, or another discontinuation 
criterion is met (Table 1 and Table 2). For the purposes of this study, “confirmed” PD is 
determined by  the Inve stigator using  RECIST v1 .1 at least every 12 w eeks w hile th e patient 
remains on treatment according to s tandard cl inical practice. There are no  mandated 
confirmatory scans , unless the  Investigator  plans to treat the  patient be yond  PD. A ll assessm ents 
on treatment days are to be performed prior to durvalumab infusion, unless otherwise indicated. 
Prior  to commenci ng infusion with durvalumab (within 3 days), the results for liver function 
tests, electrolytes , full blood count, and creatinine m ust be available and reviewed by the treating 
physician or Investigator. Patients will unde rgo various assessments for vital signs (including  
temperature, respirator y rate, blood pressure, body weight, and pulse), concomitant medication, 
laboratory, safet y, adverse event/ serious adver se event, and tumor  assessments. S afety 
assessments will be  performed a ccording  to th e National Cancer Institute Common Terminology 
Criteria for Adverse Events v5.0. A ny assess ments which ar e relevant  to preservation of  patient 
safet y, as scheduled i n the parent clinical st udy, will be conducted and followed up as per the 
SoA for this study. 
Upon discontinuation of durvalumab, for both Cohort 1 and among the patients who undergo 
retreatment in Cohort 2, follow-up will continue as per the SoA for Cohort 3 (Table 3).  Only one 
course of  retreatment  is allowed ( inclusive  of any retreatment  in the  parent clinica l study). 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 13 For patients receiving durvalumab monotherapy 
• Patients may delay dosing under certain circumstances:
−Dosing may be delayed per the Dosing Modification and Toxicity Management
Guidel
ines, due to either an immune or a non- immune -related AE (Annex 1).
−If dosing must be delayed for reasons other than treatment- rela ted toxicity, dosing
will resume as soon as feasible.
−Subsequent time between 2  consec utive doses cannot be less than 21 days, based
on the half- lives of durvalumab (see current Investigator’s Brochure for
durvalumab).

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 14Table  1 Schedule of assessments for patients currently receiving treatment wit h durvalumab monotherapy 
(Cohort 1) 
C1 C2 C3 C4 C5 onwardsa 
Week  Baselineb/ 
Enrollment 0 Q4W ±3 days unless dosing needs to be held for toxicity 
reasons  
Day 1 Q28da ys ±3 days unless dosing needs to be held for toxicity 
reasons  
Informed consent 
Informed consentc X 
Eligibility criteriad X 
Study procedures  
Vital signse X X X X X X 
Physical examinationf X X X X X X 
WHO/ECOG performance status  X X X X X X 
Concomitant medications  X X X X X X 
Laboratory safety assessments  
Clinical chemistryg X X X X X X 
Hematologyg X X X X X X 
TSH (reflex free T3 or free T4)h X X X X X X 
Pregnancy testi X X X X X X 
Monitoring  
AE/SAE assessmentj X X X X X X 
Study drug administrationk 
Durvalumab (monotherapy)l X X X X X 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 15 C1 C2 C3 C4 C5 onwardsa 
Week  Baselineb/ 
Enrollment 0 Q4W ±3 days unless dosing needs to be held for toxicity 
reasons  
Day 1 Q28da ys ±3 days unless dosing needs to be held for toxicity 
reasons  
Tumor assessment  
Tumor assessmentm Xn Assessment performed according to RECIST v1.1 as determined by the Investigator (at 
least every 12 weeks) until withdrawal of consent, progression or death.  
a.Patients will continue their assigned  treatment and all assessments Q4W (±3 days) until confirmed PD, unless unacceptable toxicity, withdrawal of  
consent, or another discontinuation criterion is met. Upon discontinuation of study drug, patients will follow the study assessments detailed in the follow-
up module (Section 7.1.1,Table 3).
b.Baseline assessments may be performed over more than 1 visit if necessary. If laboratory or imaging procedures were performed for alternate reasons  
prior to signing the consent,  these can be used for baseline assessment purposes with consent of the patient. However, all baseline laboratory 
assessments must be obtained within 3 days prior to Day 1 (first treatment visit). Baseline laboratory  assessments performed w ithin 3 days prior to Day 1 
do not need to be repeated at Day 1.
c.Informed consent of study procedures may be obtained prior to enrollment, if necessary. Patients in Cohort 1 will sign the treatment ICF.
d.Patient eligibility criteria specific to Cohort 1 that may  require additional baseline assessments to be documented and/or performed are described in  
Sections 5.1 and 5.2.
e.Vital signs include temperature, respiratory rate,  BP, and pulse. Body weight is measured along with vital signs. Vital signs should be measured,  
collected/recorded in eCRF prior to the start of the infusion. Patients should be carefully monitored, and BP and other vital signs should be measured  
during and post infusion as per institution standard and as clinically indicated.
f.Physical examination will include assessments of the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital,  
musculoskeletal, neurological, dermatological, hematologic/lymphatic,  and endocrine systems. Targeted physical examinations are to  be utilized by the  
Investigator on the basis of clinical observations and symptomatology. A physical examination should be performed 30 days (±3 days) after treatment  
discontinuation (Table 3). Situations in which physical examination results should be reported as AEs are described in  Section 8 .3.7.
g.Serum or plasma chemistry, hematology, and/or LFT monitoring may be performed more frequently if clinically indicated.  Results for urea and  
electrolytes,  full blood count, and liver function tests must be available before commencing an infusion.
h.Free T3 or free T4 will only be measured if TSH is abnormal or if there is clinical suspicion of an AE related  to the endocrine system.
i.For women of childbearing potential only. A urine or serum pregnancy test is acceptable. Women of childbearing potential are required  to have a 
pregnancy test within 7 days prior to the first dose of study drug and then every 4 weeks. Pregnancy test may occur on Day 1 of each cycle, but results  
must be available and reviewed by the treating  physician or Investigator prior to commencing an infusion. A pregnancy test should also be performed 
30 days (±3 days) after treatment discontinuation (Table 3 ). Further pregnancy testing after 30 days of treatment discontinuation should be conducted as  
clinically indicated.
j.For AEs and SAEs reported during the study, additional information such as concomitant medications will be needed.  Medical history previously  
recorded in the parent clinical study will be made available in the present study and does not need to be collected. AE/SAE assessment will be 
performed according to CTCAE v5.0.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 16  k.Patients will receive durvalumab monotherapy until confirmed PD. Section 6.6 details recommendations for patient management after the end of the  
study.
l.Results for LFTs, electrolytes, full blood count, and creatinine must be available before commencing  an infusion (within 3 days) and reviewed by the  
treating physician or Investigator prior to dosing.
m.Disease progression during treatment should be confirmed by the Investigator according to RECIST v1.1 modified for confirmation of progression, as  
described in A ppendix C.
n.The baseline imaging results from the parent clinical study will be used for baseline tumor assessments for Cohort 1.
Note: All assessments on treatment days are to be performed prior to infusion, unless otherwise indicated.
Cohort 1 will move to SoA for Cohort 3 after durvalumab treatment ends.
AE adverse event; BP blood pressure; C Cycle; CTCAE v5.0 Common Terminology Criteria for Adverse Events version 5.0; ECOG Eastern Cooperative 
Oncology Group; eCRF electronic case report form; GI gastrointestinal; HBV hepatitis B virus; HCV hepatitis C virus; HIV human immunodeficiency virus;  
ICF informed consent form; LFT liver function test; PD progressive disease; Q28days every 28 days; Q4W every 4 weeks; RECIST v1.1 Response  
Evaluation Criteria in Solid  Tumors version 1.1; SAE serious adverse event; SoA schedule of activities; SoC standard of care; T3 triiodothyronine; T4  
thyroxine; TSH thyroid-s timulating hormone; WHO World Health Organization.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 17 Table  2 Schedule of assessments for patients who completed treatment with durvalumab monotherapy or 
durvalumab in combination with any other approved or investigational anticancer agents, and are eligible 
for future retreatment (Cohort 2)  
Follow -up before retreatment Retreatment  
Time since the last dose of study 
drugaLong-term follow -up Baseline
b/ 
C1 C2 C3 C4 C5 onwards
c 
Week  Baseline/  
EnrollmentaDay (±3 days)
 Day 
(±7 days) Every 3 months (±2 weeks)0 Q4W ±3 days unless dosing needs to be held f
or toxicity reasons 
Day 30 60 90 1 Q28days ±3 days unless dosing needs to be hel
d for toxicity reasons 
Informed consent  
Informed consent Xd Xe 
Eligibility criteria  Xd Xe 
Study procedures  
Vital signsf X X X X X X X X 
Physical examinationg X X X X X X 
WHO/ECOG performance 
status  X X X X X 
Concomitant medications  X X X X X X X X 
Laboratory safety assessments 
Clinical chemistryh X X X X X X X X 
Hematologyh X X X X X X X X 
TSH (reflex free T3 or free T4)
i X X X X X X X X 
Pregnancy testj X X X X X X 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 18  Follow -up before retreatment Retreatment  
Time since the last dose of study 
drugaLong-term follow -up Baseline
b/ 
C1 C2 C3 C4 C5 onwards
c 
Week  Baseline/  
EnrollmentaDay (±3 days)
 Day 
(±7 days) Every 3 months (±2 weeks)0 Q4W ±3 days unless dosing needs to be held f
or toxicity reasons 
Day 30 60 90 1 Q28days ±3 days unless dosing needs to be hel
d for toxicity reasons 
Monitoring  
AE/SAE assessmentk X X X Throughout  
Survival statusl X 
Study drug administration  
Durvalumab (monotherapy)m X X X X X 
Tumor assessment  
Tumor assessmentn Assessment performed according to the Investigator’s 
standard practice until withdrawal of consent, progression or 
death.  Xo Assessment performed according to 
RECIST  v1.1 as determined by the 
Investigator (at least every 12 weeks) until 
withdra wal of consent, progression or death.  
a.Follow-u p visits are performed based on the duration since the last dose of study drug in either the parent clinical study or current study  (whichever  
most recently administered the study drug). Patients who are more than 90 days beyond the last dose of study drug, will not undergo follow-u p for AEs/
SAEs, vital signs, concomitant medications, or laboratory safety assessments; these patients will be followed for survival and undergo tumor  
assessment per Investigator’s standard practice.
b.Baseline assessments may be performed over more than 1 visit if necessary. If laboratory or imaging procedures were performed for alternate reasons 
prior to signing the consent, these can be used for baseline assessment purposes with consent of the patient. However, all baseline laboratory  
assessments must be obtained within 3 days prior to Day  1 (first retreatment visit), and baseline imaging results must be obtained within 28 days prior 
to Day 1 of retreatment.  Baseline laboratory assessments performed within 3 days prior to Day 1 do not need to be repeated at Day 1. Patients with  
documented HIV test results from the parent clinical study do not need to undergo a repeat test, but HBV and HCV must be retested within the 28-d ay 
period.
c.Patients will continue their assigned treatment and all C5 assessments Q4W until confirmed PD, unless unacceptable toxicity, withdrawal of consent, or 
another discontinuation criterion is met. Upon discontinuation of study drug, patients will follow the study assessments detailed in the follow-u p 
module (Section 7.1.1, Table 3). Section 6.6 details recommendations for patient management after the end of the study.
d.Informed consent of study procedures may be obtained prior to enrollment, if necessary.  Patients in Cohort 2 will sign the follow-u p ICF while off  
treatment, and must meet the eligibility criteria detailed in Sections 5.1 and 5.2.
e.Patients must agree to reconsenting (treatment ICF) to start retreatment and must meet the eligibility criteria detailed in Sections 5.1 and 5.2 prior to  
starting retreatment.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 19 f.Vital signs include temperature, respiratory rate,  BP, and pulse. Body weight is measured along with vital signs. Vital signs should be measured,  
collected/recorded in eCRF prior to the start of the infusion. Patients should be carefully monitored, and BP and other vital signs should be measured  
during and post infusion as per institution standard and as clinically indicated.
g.Physical examination will include assessments of the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital,  
musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Targeted physical examinations are to be utilized by the  
Investigator on the basis of clinical observations and symptomatology.  A physical examination should be performed 30 days (±3 days) after last dose of 
study drug and discontinuatio n of retreatment (Table 3). Situations in which physical examination results should be reported as AEs are described in  
Section 8.3.7.
h.Serum or plasma chemistry, hematology, and/or LFT monitoring may be performed more frequently if clinically indicated. Results for urea and  
electrolytes,  full blood count, and liver function tests must be available before commencing an infusion.
i.Free T3 or free T4 will only be measured if TSH is abnormal or if there is clinical suspicion of an AE related to the endocrine system.
j.For women of childbearing potential only. A urine or serum pregnancy test is acceptable.  Women of childbearing potential are required to have a  
pregnancy test within 7 days prior to the first dose of study drug and then every 4 weeks. Pregnancy test may occur on Day 1 of each cycle, but results 
must be available and reviewed by the treating physician or Investigator prior to commencin g an infusion.  A pregnancy test should also be performed 30  
days (±3 days) after last dose of study drug  and discontinuation of retreatment (Table 3). Further pregnancy testing after 30 days of treatment  
discontinuation should be conducted as clinically indicated.
k.For AEs and SAEs reported during the study, additional information such as concomitant medications will be needed. Medical history previously  
recorded in the parent clinical study will be made available in the study and does not need to be collected. AE/SAE assessment will be performed 
according to CTCAE v5.0.
l.Upon completing the 90-d ay follow-up for AEs and SAEs, patients wi ll be followed for survival.  Survival follow-u p will be performed by  telephone call  
(or a prespecified preferred method of contact, as an alternative). Patients will be contacted by telephon e in the week following data cut-o ffs to confirm  
survival status. No additional retreatment with durvalumab will be allowed.
m.Results for LFTs, electrolytes, full bloo d count, and creatinine must be available before commencing an infusion (within 3 days) and reviewed by  the 
treating physician or Investigator prior to dosing.
n.Disease progression during treatment should be confirmed by the Investigator according to RECIST 1.1 modified for confirmation of progression, as  
described in Appendix C.
o.The most recent imaging results from the parent clinical study may be used as the baseline assessment, provided it was obtained within 28 days prior to  
Day 1.
Note: Cohort 2 will move to SoA for Cohort 3 after retre atment with durvalumab ends.  
AE adverse event; BP blood pressure; C Cycle; CTCAE v5.0 Common Terminology Criteria for Adverse Events version 5.0; ECOG  Easte rn Cooperative 
Oncology Group; eCRF electronic case report form; GI gastrointestinal; HBV hepatitis B virus; HCV hepatitis C viru s; HIV human immunodeficiency virus; 
ICF informed consent form; LFT liver function test; PD progressive disease; Q28days every 28 days; Q4W every 4 weeks; RECIST 1.1 Response 
Evaluation Criteria in Solid Tumors version 1.1; SAE serious adverse event; SoA s chedule of activities; SoC standard of care; T3  triiodothyronine; T4 
thyroxine; TSH thyroid -stimulating hormone; WHO World Health Organization.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 20  Table  3 Schedule of assessments for patients who previously received treatment with durvalumab monotherapy or 
durvalumab in combination with any other approved or investigational anticancer agents, and are not eligible 
for any future treatment (Cohort 3)  
Time since the last dose of 
study druga Long -term follow -up 
Evaluation  Baseline/ 
Enrollment Day (±3 
days)  Day (±7 days)  Every 3 months (±2 weeks)  
30 60 90 
Informed consent  
Informed consentb X 
Eligibility criteriab X 
Study procedures  
Vital signsc X X X 
Physical examinationd X 
Concomitant medications  X X X 
Subsequent anticancer therapye X X X X X 
Laboratory safety assessments  
Clinical chemistry  X X X 
Hematology  X X X 
TSH (reflex free T3 or free T4)f X X X 
Pregnancy testg X 
Monitoring  
AE/SAE assessmenth X X X 
Survival statusi X 
Tumor Assessments  
Tumor assessmentj Assessment performed according to the Investigator’s standard practice until withdrawal of consent, 
progression or death.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 21a.Follow-u p visits are performed based on the duration since the last dose of study drug in either the parent clinical study or current study  (whichever  
most recently administered the study drug). Patients who are more than 90 days beyond the last dose of study drug will not undergo follow-u p for AEs/
SAEs, vital signs, concomitant medications or laboratory safety assessments; these patients will be followed for survival.
b.Informed consent of study procedures may be obtained prior to enrollment, if necessary. Patients in Cohort 3 will sign the follow-u p ICF, and must meet  
the eligibility  criteria detailed in Sections 5.1 and 5.2.
c.Vital signs include temperature, respiratory rate, BP, and pulse. Body weight is measured along with vital signs.
d.Physical examination should be performed 30 days (±3 days) after treatment discontinuation. A physical examination will include assessments of the 
head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological,
hematologic/lymphatic, and endocrine systems. Targeted physical examinations are to be utilized by the Investigator on the basis of clinical  
observations and symptomatology. Situations in which physical examination results should be reported as AEs are described in Section  8.3.7.
e.Only the first subsequent anticancer therapy regimen used after durvalumab discontinuation will be collected.
f.Free T3 or free T4 will only be measured if TSH is abnormal or if there is clinical suspicion of an AE related to the endocrine system.
g.Pregnancy test should be performed 30 days (±3 days) after treatment discontinuation. Further pregnancy testing after 3 0 days of treatment  
discontinuation should be conducted as clinically indicated.
h.For AEs and SAEs reported during the study, additional information such as concomitant medications will be needed.  Medical history previously 
recorded in the parent clinical study will be made available in the study and does not need to be collected. AE/SAE assessment will be performed  
according to CTCAE v5.0.
i.Upon completing the 90-d ay follow-up for AEs and SAEs, patients will be followed for survival. Survival follow-u p will be performed by telephone call  
(or a prespecified preferred method of contact,  as an alternative). Patients will be contacted by telephon e in the week following data cut-o ffs to confirm  
survival status.
j.Tumor assessment of best overall response to the first subsequent treatment after durvalumab, only (where evaluable). After that, tumor assessments 
will no longer be required for long-t erm follow-u p.
Note: Following discontinuation of study drug, patient s who  decline to return to the site for evaluations should be contacted by telephone, or their prespecified 
preferred method of contact, as an alternative.  
AE adverse event; BP blood pr essure; CTCAE v5.0 Common Terminology Criteria for Adverse Events version 5.0; PD progressive disease; SAE serious ad verse 
event; SoC  standard of care; T3 triiodothyronine; T4 thyroxine; TSH thyroid -stimulating hormone.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 23 • Cohort 2: includes patients who completed durvalumab mono therapy or in
combination with any other approved or investigational anticancer agents in a parent
study, without confirmed PD during the period of treatment, and who are potentially
eligible for retreatment with durvalumab . The patient should not have received any
other approved or investigational anticancer agents since completion of durvalumab
treatment. Patients who completed the prespecified duration of treatment with
durvalumab in a parent clinical study, who received clinical benefit and thensubsequently experienced confirmed PD after completion of planned treatment, will be
permitted to restart durvalumab treatment provided they meet the eligibility criteria. If
a patient was already retreated with durvalumab in the parent clinical study andretreat ment has ended, they are no longer eligible for retreatment in this study.
• Cohort 3: includes patients previously treated with durvalumab monotherapy or incombi na
tion with any other approved or investigational anticancer agents who are no
longer receiving durvalumab and are not eligible to receive retreatment.
In addition to providing continued treatment to eligible patients, the study will monitor long- term 
saf
ety of durvalumab and OS (Cohorts 1 to 3).  
Study Period:  
Estimated date o f first pa tient enrolled:  Q3 2019 
Estimated date of last patient visit completed  is Q4 2022.  
Numb
er of patients: This study will enroll patients who have been previously treated with 
durvalum
ab and/or durvalumab in combination with any other approved or investigational 
antic ancer agents at any global site. The study will enroll up to 600 patients. The number of 
patients is subject to change as new parent studies are included into this long- term safety and 
efficacy study.  
Treatment and treatment duration 
Patients in Cohort 1 and those going onto durvalumab retreatment in Cohort 2 will receive 
durvalum
ab monotherapy. Patients in Cohort 3 will not receive any study drug.  
Durvalumab monotherapy 
• Durvalumab 1500 mg via intravenous (IV) infusion every 4 weeks until confirmed PD,
unless
 unacceptable toxicity, withdrawal of consent, death, or another discontinuation
criterion is met. Please note, if a patient’s weight falls to 30  kg or below (≤30 kg), then
the patient should receive weight-based dosing equivalent to 20 mg/kg of durval umab
q4w after consultation between Investigator and Study Physician, until the weight
improves to above 30 kg (>30 kg).

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 24 Duration of treatment 
Patients in Cohort 1 will continue to receive treatment with durvalumab until confirmed PD. This 
includes
 patients who received durvalumab monotherapy or combination therapy under the 
parent clinical study, and who are eligible to continue durvalumab treatment after completing 
dosing of any other approved or investigational anticancer agents, which are a formal component 
of the parent study. 
Continuation with durvalumab monotherapy (Cohort 1) and retreatment with durvalumab 
monothera
py (Cohort 2) will continue until confirmed PD, unless unacceptable toxicity, 
withdrawal of consent, death, or another discontinua tion criterion is met. Patients will only be 
eligible for 1  course of retreatment (inclusive of any retreatment in the parent clinical study and 
this study). Patients will not be eligible to receive retreatment with any other approved or 
investigational anticancer agents administered in the parent clinical study. Disease progression 
will be determined by the Investigator following Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).  
Cohort 3 includes patients who have previously received durvalumab treatment or durvalumab 
combin a 
tion therapy and are not eligible for future treatment. These patients will be followed for 
OS. 
Progression during treatment  
Patients receiving the study drug who experience disease progression and, in the  Investigator’s 
opinion, continue to receive benefits from their assigned treatment; may continue to receive the 
study drug for as long as they meet specific clinical criteria, and are deriving clinical benefit in 
the opinion of the Investigator.  
For all patients who are treated through progression, the Investigator should ensure that patients 
still mee
t all the inclusion criteria and none of the exclusion criteria for this study, and obtain 
additional informed consent for continuation of treatm ent. This consent addendum document will 
be part of the treatment informed consent form (ICF); it will specify that treatment beyond initial evidence of PD is not the standard of care and that alternative treatment options, either locally 
licensed treatmen ts or other clinical trials, are potentially available for this patient population. 
Patients with rapid tumor progression or with symptomatic progression that require medical 
intervention (eg, central nervous system metastasis, respiratory failure due to tumor compression, 
spinal cord compression) will not be eligible for continuing durvalumab.  
Follow up of patients post discontinuation of study drug  
Treatment is given until progression, unless there is unacceptable toxicity, withdrawal of 
consent , 
or anot her discontinuation criterion is met. Patients in Cohort 1 who discontinue 
durvalumab for any reason will not be eligible for further retreatment and will be followed 
subsequently for safety and survival. All patients in the study will be followed for safe ty for 
90 days after the last dose of durvalumab and for OS and may receive any subsequent anticancer 
therapy at the discretion of the Investigator. The details of first subsequent anticancer therapy 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 25 and overall best response after discontinuation of durva lumab treatment will be collected from 
the Investigator.  
Survival 
All patients in the study are followed up for survival every 3 months (±2 weeks) beginning 
90 days aft
er the last dose of the study drug. Patients who enter Cohort 3 are in survival 
follow -up from the time of enrollment since no study drug is being administered to that cohort. 
Survival information may be obtained via telephone contact (or a prespecified preferred method of contact, as an alternative) with the patient or the patient’s family, or by contact with the 
patient’s current physician.  
Statistical methods and endpoints  
The primary objective is to monitor long- term sa f
 ety of durvalumab. The safety analysis set will 
be used to summarize safety data according to the treatment received for all patients who 
received at least one dose of durvalumab. This analysis set would include patients continuing study treatment or retreatment, and those who enrolled in this study within 90 days of the last 
dose of durvalumab or durvalumab combination on the respective parent clinical study. Adverse 
events (AEs), vital signs and laboratory safety assessments (clinical chemistry, hematology and Thyroid- stimulating hormone [reflex free triiodothyronine or free thyroxine]) will be listed 
individually by patie nt. The number of patients experiencing each AE will be summarized by 
cohort and the National Cancer Institute Common Terminology Criteria for Adverse Events grade (v5.0) (Annex 1).  
The analysis set for assessment of efficacy will be based on patients who  are r et
 reated with 
durvalumab in Cohort 2. Efficacy analysis will be performed only if there is sufficient sample 
size; if s
o, data may be summarized by tumor type in each tumor type, otherwise , only listings 
will be
 provided as descriptive results. 
One s econdary objective is to assess the efficacy of durvalumab in terms of ORR and DOR for 
durva
lumab retreatment patients. ORR is defined as the number (%) of patients with at a 
confirmed response of complete response (CR) or partial response (PR). DOR is def ined as the 
time from first documented of CR or PR until the time of first documented disease progression or 
death in the absence of disease progression since re- initiation of durvalumab treatment. Tumor 
assessments will be performed by computed tomography scans per standard practice (at least every 12 weeks). Tumor assessments will be performed by the Investigator according to RECIST v1.1; only the response outcomes will be collected in the case report form.  
The OS is defined as the time from date of randomization/enrollment in the parent clinical study 
until t
he date of death by any cause. A listing of OS data will be provided for all study patients.  
In addition, OS and tumor efficacy data in this study may be combined with the parent study data 
for inte grat
ed analysis.  
No statistical methods will be employed to test a specific hypothesis in this study. In addition to 
the 5 plann
ed interim analyses, ad hoc analyses may be performed at various time points in order 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001
CONFIDENTIAL AND PROPRIETARY 26to support publications, internal decision making by AstraZeneca, and/or regulatory submissions 
as appropriate.  
Sample size estimate
The number of patients enrolled in this study will be determined by the number of patients who 
received durvalumab and/or durvalumab in combination with any other approved or 
investigational anticancer agents in original trials, and who wish to participate, and who meet the eligibility criteria. The study will enroll up to 600 patients and the number of patients may change as new parent studies are included into this long- term safety and efficacy study.
1.3 Schema
The general study design for this study is summarized in Figure 1.  
Figure 1 Study des ign
SD stable disease.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 27 2. INTRODUCTION
2.1 Study rationale
This is a multicenter, open -label, global study that will enroll patients who are currently 
receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or 
in combination with any other approved or investigational anticancer agents, in an eligible 
AstraZeneca/MedImmune- sponsored clinical study (herein referred to as a parent clinical study). 
The aims of the study are the following: 
• To collect long -ter m safety and survival data from patients who received durvalumab
monotherapy and/or durvalumab in combination with any other approved or
investigational anticancer agents.
• To provide continued access to durvalumab monotherapy until confirmed progressive
disease (
PD) to patients currently receiving treatment.
• To allow for future retre atme nt with durvalumab monotherapy upon disease
progression in patients who previously benefited from treatment with durvalumab asmonotherapy, and/or durvalumab in combination with any other approved or
investigational anticancer agents and experienced disease progression after completionof planned treatment.
The primary aim of this study is to monitor the long -term sa
 fety of durvalumab. Extensive 
safety -related data are being collected throughout the course of drug development, and 
knowledge about a drug’s safety profile continually evolves as safety data accumulate. This 
study is aligned with the growing interest in larger, simpler trials to obtain outcome data, 
including long- term effects of drugs and comparative effectiveness and safety.  
2.2 Background 
A detailed description of the chemistry, pharmacology, efficacy, and safety of durvalumab is 
provided in the Investigator’s Brochure (IB).  
2.2.1 Immunotherapies  
It is increasingly understood that cancers are recognized by the immune system, and under some 
circumstances,
 the immune system may control or even eliminate tumors (Dunn e t al 2004).  
Programmed death ligand 1 (PD- L1) is pa rt of a complex system of recep tors and ligands that are 
involved in controlling T cell activation. The programmed cell death protein 1 (PD-1 ) receptor 
(CD279) is expressed on the surface of activated T cells ( Keir et al 2008). It has 2 known 
ligands: PD-L 1 (B7-H1; CD274) and PD-L 2 (B7-D C; CD273) (Okazaki and Honjo 2007 ). PD-1 
and PD- L1/PD -L2 belong to a family of immune checkpoint proteins that act as co- inhibitory 
factors, which can halt or limit the development of T cell response. When PD-L1 binds to PD-1, 
an inhi bitory s ignal is transmitted into the  T cell, which reduces cytokine producti on and 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 28 suppresses T ce ll proliferation.  Tumor  cells e xploit this im mune  checkpoint pathway as a 
mechanism to evade detection and inhibit immune response. 
PD-L1 is constitutively expressed by B-c ells, dendritic cells, and macrophages (Qin et al 2016). 
Importantly, PD-L1 is commonly over-expressed on tumor cells or on non-t ransformed cells in 
the tumor microenvironment (Pardoll 2012). PD-L1 expressed on the tumor cells binds to PD-1 
receptors on  the activated T cells, leading to the inhibition of cytotoxic T cells. These deactivated 
T cells re main inhibited i n the tumor microenvironment. The  PD-1/PD -L1 pathway represents an 
adaptive immune resistance mechanism that is exerted by  tumor  cells in response to en dogenous 
antitumor activity.  
The inhibitory mechanism describe d above is co-opted by tumors that express PD-L1 as a way of  
evading immune detection and elimination. The binding of an anti- PD-L1 agent to the PD-L1 
receptor inhibits th e interaction  of PD-L1 with the PD-1 and CD80 receptors expressed on 
immune c ells (IC ). This activity ove rcomes P D-L1-mediated inhibiti on of antitumor immunity. 
While functional blockade of PD-L1 re sults in T ce ll reactivation,  this mechanism of action 
(MOA) is different from direct agonism of a stimulatory receptor such as CD28. 
PD-L 1 is expressed in a broad range of cancers. Based on these findings, an anti-P D-L1 antibody 
could be used therapeutically to enhance antitumor immune responses in patients with cancer. 
Results of preclinical and clinical studies of monoclonal antibodies (mAbs) targeting the 
PD-L 1/PD-1 pathway have shown evidence of clinical activity and a manageable safety profile, 
supporting the hypothesis that an anti-P D-L1 antibody could be used to therapeutically enhance 
antitumor immune response in cancer patients (Brahmer et al 2012, Hirano et al 2005, 
Iwai et al 2002, Okudaira et al 2009, Topalian et al 2012, Zhang et al 2008) with responses that 
tend to be more pronounced in patients with tumors that express PD-L 1 (Powles et al 2014,  
Rizvi et al 2015, Segal et al 2015 ). In addition, high mutational burden (eg, in bladder 
carcinoma; Alexandrov et al 2013) may  contribute to the responses seen with immu ne therapy. 
Preclinical data has now been ad ded to a wealth of clinical d ata showing that blockade of 
negative regulatory signals to T c ells suc h as cytotoxic T -lymphocyte- associated ant igen-4 
(CTLA -4) and PD- L1 ha s promising c linica l activity.  Ipilimumab w as first granted United S tates 
(US) Food  and Drug Administration  (FDA) approval for  the treatment of  metastatic melanoma 
and is currently under investigati on for several other malignancies. Nivolumab and 
pembrolizumab, 2 anti- PD-1 age nts, and  atezolizumab , an anti- PD-L1 agent, have been granted 
approvals by agencies for the treatment of a number of malignancies , including metastatic 
melanoma, squamous and non-squamous cell non-small ce ll lung  cancer (NSCLC), s quamous  
cell carcinoma of  the head and  neck, and ur othelial carcinoma. In a ddition,  there are data f rom 
agents in the anti-PD-1/PD -L1 class s howing  clinical activity in a w ide range of tumo r types. 
2.2.2 Durvalumab 
Durva l
umab is a human mAb of the immunoglobulin G (IgG) 1 kappa subclass that blocks the 
interac
tion of PD-L1 (but not programmed cell death ligand- 2) with PD -1 on T cells and CD80 
(B7.1) on IC. It is being developed by AstraZeneca/MedImmune, for use in the treatment of 
cancer. (MedImmune is a wholly owned subsidiary of AstraZeneca; AstraZeneca/Med Immune 
will be referred to as AstraZeneca throughout this document.) The propose MOA for durvalumab 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 30 2.3 Benefit/risk assessment  
More detailed information about the known and expected benefits and risks, and reasonably 
expected adverse events ( AEs) of durvalumab may be found in the  IB. 
2.3.1 Overall benefits  
As is c
ommonly the case for clinical trials with a fixed treatment or study duration, long -term 
saf
ety and efficacy endpoints often lack feasibility within the time frame permitted by design. 
The benefit of this study, which ide ntifies potentially eligible patients from parent clinical 
studies, allows for the continued access of durvalumab and observation of patients treated with durvalumab. Durvalumab will be provided to eligible, treatment-experienced patients who have 
been tre ated for months under parent clinical studies and have demonstrated a response and 
tolerability to treatment. They will be treated as long as they continue to receive benefit for 
treatment with durvalumab.  
Conducting this study serves the important purpose to better understand the long- term pat
 ient 
safety and survival outcomes across a diverse group of patient population exposed to durvalumab.  
2.3.1.1 Benefits of durvalumab as monotherapy 
The ma
jority of the safety and efficacy data currently available for durvalumab are based on 
5 monother
apy studies (CD -ON-MEDI47361108, ATLANTIC, HAWK, PACIFIC, and 
D4190C00007) for which efficacy data are available. Data from these studies have demonstrated 
clinical activity of d urvalumab therapy in patients with NSCLC. PACIFIC has shown significant 
improvements in median progression -free survival with durvalumab treatment compared with 
placebo for patients with NSCLC (16.8 months [95% confidence interval {CI}: 13.0, 18.1] versus 5.6 months [95% CI: 4.6, 7.8]; stratified hazard ratio for disease progression or death, 
0.52; 95% CI: 0.42, 0.65; p<0.001). Similar findings in favor of durvalumab compared with 
placebo were found for duration of response ( DOR ; 72.8% versus 46.8% of patients had ongoing 
response at 18 months, respectively) and median time to death or distant metastasis (23.2 months 
versus 14.6 months, respectively; p<0.001). 
2.3.2 Overall risks 
Monocl ona
l antibodies directed against immune checkpoint proteins, such as PD- L1 as well  as 
those directed against PD- 1 or CTLA -4, aim to boost endogenous immune responses directed 
against tumor cells. By stimulating the immune system, however, there is the potential for 
adverse effects on normal tissues.  
Most adverse drug reactions seen w ith the i mmune checkpoint inhibitor class of agents are 
thought to be due to the effects of inflammatory cells on specific tissues. These risks are generally events with a potential inflammatory or immune -mediated mechanism and that may 
require more freque nt monitoring and/or unique interventions, such as immunosuppressants 
and/or endocrine therapy. These immune- mediated effects can occur in nearly any organ system 
and are most commonly seen as gastrointestinal (GI) AEs such as colitis and diarrhea, 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 31 pneumoni tis/interstitial l ung disease (ILD), he patic AEs such as liver enz yme elevations, skin 
events such as rash a nd dermatitis, and endocrinopathies including hypo- and hyperthyroidism. 
2.3.2.1 Potential r isks of  durvalumab monotherapy 
Risks with durvalumab include, but  are not  limited to, di arrhea/colitis, pn eumonitis/ILD, 
endocrinopathies (ie , events of hypop hysitis/hypopituitarism , adrenal insufficiency, hyper- and 
hypothyroidism, a nd type I diabetes mellitus [D M]), h epatitis/increases i n transaminases, 
nephritis/increases in c reatinine, pa ncreatitis/increases in a mylase and  lipase, r ash/dermatitis, 
myocarditis, myos itis/polymyositis, other rare o r less frequent inflammatory e vents including  
neuromuscular toxicities, infusion -related re actions, hypersensitivity re actions, and 
infections/serious  infections. 
For information  on a ll identified a nd potentia l risks  with dur valumab,  please a lways  refer to the  
current version of the durvalumab IB. 
In monotherapy clinical studies, AEs reported an incidence of ≥20%, this included eve nts such as 
fatigue, cough, decreased appetite, dyspnea, and nausea. A total of 5% to 10% of pa tients 
discontinued the drug due to an AE. Please see the current version of the IB for a detailed 
summary of the m onotherapy data including AEs, serious adverse events (SAEs), and C ommon  
Terminology C riteria G rade 3 to 5 e vents re ported a cross the durvalumab program. 
The majority of  treatment -related A Es were manageable with dos e delays, symptomatic 
treatment, and  in the case of events suspected  to have an immune basis, the use of established 
treatment guidelines for immune-mediated  toxicity (see Section 8.4.4). 
A detailed summary of durvaluma b monotherapy AE data can be found in the current version of 
the durvalumab IB. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 32 3. OBJECTIVES AND ENDPOINTS
The objectives an d endpoints for this study are listed in  Table 4 . 
Table 4  Study obje ctives  
Primary Objective: Endpoints/Variables: 
To monitor long-term safety of durvalumab (all 
cohorts)  •All SAEs
•Non-serious AEs that lead to dose modification,
drug discontinuation, or withdrawal from the
study
•All Grade 3 and Grade 4 AEs
•Grade 2 AEs that affect vital organs (eg, heart,liver)
•Immune- mediated AE s
•Laboratory findings qualifying as an SAE/AE
(endpoints defined above) up until 90 days after
the last dose of durvalumab in all patients
Secondary Objectives: Endpoints/Variables: 
To assess the efficacy of durvalumab in terms 
of ORR and DOR in patients who undergo 
retreatment with durvalumab (Cohort 2 only)a •ORR:  Number (%) of patients with a confirmed
response of CR or PR.
•DOR:  Time from first documented CR or PR to
time of first documented disease progression or
death in the absence of disease progression
To assess the OS of patients (all cohorts)  •OS: Time from date of
randomization/enrollment in the parent clinical
study unt il the date of death by any cause
AE adverse event; CR complete response; DOR duration of response; ORR overall response rate; OS overall 
survival; PR partial response; SAE serious adverse event.  
a.To be performed only if there is sufficient sample size in retreated Cohort 2 patients to evaluate efficacy;
otherwise, only listings will be provided for this objective (Section 6.6)
4. STUDY DESIGN
4.1 Overall design
This is a multicenter, open -label, global study that will enroll patients who are currently 
receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or 
in combination with any other approved or investigational anticancer agents, in an eligible parent 
clinical study. The study aims to enroll up to 600 patients; study si ze may increase as new parent 
clinical studies are incorporated into this study. Some of these patients will no longer be eligible 
to receive treatment or retreatment with durvalumab, and will be followed for overall survival 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 33 (OS). For patients w ho are eligible to c ontinue  treatment or  restart durvalumab,  treatment will be  
administered every 4 weeks (q4w; ±3 days ) until PD, unless there is unacceptable toxicity, 
withdrawal of consent , death, or another discontinuation criterion is met. All patients in the study 
will be followed for safety for 90 days after the last dose of durvalumab, and every 3 months (±2 
weeks) beginning 90 days after the last dose of study drug for OS. For an overview of the study 
design, see Section 1.3. For details on treatments given during the study, see Section 6.1. Upon 
discontinuation of durvalumab, patients may receive any subsequent anticancer therapy at the 
discretion of the Investigator (Section 7.1). 
4.2 Scientific rationale for study design  
4.2.1 Rationale for retreatment option  
In contrast to patients treat ed with chemotherapy, who are unl ikely to respond to re- challenge 
with the same agent upon progression, respons es have been o bserved up on retreatment w ith 
immunotherapies. S everal potentia l mechanisms of  resistance to i mmunotherapy  exist, inc luding  
loss of  T ce ll “memory”  or recurrence of  immune  escape , which sugge sts that r etreatment  for 
patients w ho initially respond or demonstrate S D is reasonable. Preliminary data in patients 
previously treated with immunotherapies suggest that responses are similar to those observed 
following initial treatment (Forde et al 2014, Hodi et al 2010).  
Durvalumab ha s been administered I V in mul tiple c linical studies up  to 12 mont hs. After the  
completion  of therapy  in the se ongo ing clinica l studies, pa tients a re followed w ith re gular tumor 
assessments to c ontinue  monitoring  the clinical activity of  durvalumab.  Emerging  data from  
these ongoing st udies suggest t hat so me patients lose clinical benefit after completing 12 months 
of therapy.  
4.3 Justification for dose 
4.3.1 Durvalumab dose and treatment regimen justification  
4.3.1.1 Durvalumab monotherapy dose rationale 
A durval
umab dose of 20 mg/kg q4w is supported by in vitro data, preclinical activity, clinical 
PK/pharma
codynamics , biomarkers, and activity data from Study CD- ON-MEDI4736-1108 
(hereafter referred to as Study 1108) in patients with advanced solid tumors and from a Phase I 
study performed in Japanese patients with advanced solid tumor (D4190C00002). 
Pharmacokinetic/ Pharmac odynamic data  
Based on available PK/ pharma codynamic data from ongoing Study 1108 with dose ranging from 
0.1 to 10 mg/kg every 2 weeks (q2w) or 15 mg/kg every 3 weeks (q3w), durvalumab exhibited 
nonlinear (dose-dependent) PK consistent with target-mediated drug disposition. The PK 
approached linearity at ≥3 mg/kg q2w, suggesting near complete target saturation (membrane -
bound and soluble PD-L1), and further showed that the durvalumab dosing frequency can be 
adapted t o a particular regimen given the linearity seen at doses higher than 3 mg/kg. The 
expected half -life with doses ≥3 mg/kg q2w is approximately 21 days. A dose -dependent 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 34 suppressi on in peripheral soluble PD-L1 was observed over the dose range studie d, consis tent 
with engagement of durvalumab with PD-L1. A low level of immunogenicity has been observed. 
No patients have experienced immune-complex disease following exposure to durvalumab. ( For 
further information on immunogenicity, please see the current durvalum ab IB.)  
A population PK model was developed using the data from Study 1108 (doses=0.1 to 10 mg/kg 
q2w or 15 mg/kg q3w; Fairman et al 2014). Multiple simulations indicate that a similar overall 
exposure is expected followi ng bot h 10 m g/kg q2w and 20 mg/kg q4w regimens , as represented 
by AUC ss (4 weeks). Me dian C max,ss is expected to be higher with 20 mg/kg q4w (~1.5 fold) and 
median C trough,ss  is expect ed to be higher with 10 mg/kg q2w (~1.25 f old). Clinical activity w ith 
the 20 mg/kg q4w dosing regimen is anticipate d to be consistent with 10 mg/kg q2w with the 
proposed similar dose of 20 mg/ kg q4w expected to (a) achieve complete target sa turation  in the 
majority of patients; (b)  account for anticipate d variability in PK, pharmacodynamics, and 
clinical activity in d iverse cancer po pulations; (c) maintain s ufficient PK e xposure in c ase of  
antidrug antibodies impact; and (d) achieve P K exposure that yielded maximal antitumor activity 
in animal models. 
Given the  similar a rea under the serum drug concentration- time c urve and modest d ifferences in 
median peak and trough levels at steady state, the observati on that both regimens maintain 
complete soluble PD-L1 suppressi on at trough, and the available clinical data, the 20 mg/kg q4w 
and 10 mg/kg q2w regimens are expected to have similar efficacy and safety profiles, supporting 
further development with a dose of 20 mg/kg q4w.  
Clinical data 
Refe r to the  curren t durvalumab IB f or a c omplete s ummary of clinical information  including  
safety,  efficacy,  and P K at t he 20  mg/kg q4w regimen.  The IB r eflects th e current regimen t hat is 
used across the program when durvalumab monotherapy is dosed q4w. 
4.3.1.2 Rationale for fixed dosing 
A popul ation PK model was developed for durvalumab using monotherapy data from 
Study 1108 (N=292; doses=0.1 to 10 mg/kg q2w or 15 mg/kg q3w; solid tumors). Population PK 
analysis indicated only a minor impact of body weight (WT) on the PK of durvalumab 
(coefficient of ≤0.5). The impact of body weight (WT) -based (10 mg/ kg q2w) and fixed dosing 
(750 mg q2w) of dur valumab was evaluated by comparing predicted steady state PK 
concentrations (5th, median, and 95th percentiles) using the po pulation PK model. A fixed dose of 
750 mg was selected t o approximate 10 mg/kg (based on median body WT of ~75 kg). A total of 
1000 patients were simulated using body WT distribution of 40 to 120 kg. Simulati on results 
demonstrate that body WT-based and fixed dosing regimens yield similar median steady state 
PK concentrations with slightly less overall between- patient variability w ith fix ed dosing 
regimen.  Similar findings have been reported by others (Narwal et al 2013, Ng et al 2006, 
Wang et al 2009, Zhang et al 2012). Wang and colleagues investigated 12 mAbs and found that 
fixed and body weight-based dosing perform similarly, with fixed dosing being better for 7 of 12 
antibodies (Wang et al 2009). In addition, they investigated 18 therapeutic proteins and 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 35 peptides, and showed that fixed dosing performed better for 12 of 18 in terms of reducing the 
betw een-patient variability in PK/pharmacodynamic parameters (Zhang et  al 2012 ).  
A f
ixed dosing approach is preferred by the prescribing community, due t o ease of us e and 
reduced dosing errors. Given the expectation of similar PK exposure and variability, AstraZeneca considered it feasible to switch to fixed dosing regimens. Based on average body 
WT of 75 kg, a fixed dose of 1500 mg q4w durvalumab (equivalent to 20 mg/kg q4w) is 
included in the current study. 
4.3.1.3 Rationale for duration of treatment 
In this 
study, the duration of treatment was selected to allow eligible patients to continue 
treat
ment with durvalumab monotherapy until confirmed PD. Additionally, patients who 
completed the defined duration of treatment with durvalumab or durvalumab plus any other 
approved or investigational anticancer agents in a parent clinical study and subsequently 
experienced confirmed PD, will be permitted to start retreatmen t with durvalumab monotherapy, 
if they meet eligibility criteria.  
4.4 End of study definition  
The end of study is expected to occur in Q4 2022 and is defined as the date of the last scheduled visit of the last participant in the study at the time of the final data cut -off (DCO).   
A participant is considered to have completed the study if he/she has completed all phases of the study inc
luding the last scheduled visit shown in the SoA at the end of study. 
Any patients in Cohort 2 or Cohort 3 not receiving treatme nt will disco ntinue further follow-up 
at the end of study.  
For patients receiving treatment in Cohort 1 or 2, refer to Section  6.6 & 8.3.14 w hich details 
recom
mendations for  patient management following study completion.  
5. STUDY POPULATION
The study population will consist of patients who are curre ntly receiving or have previously 
received durvalumab monotherapy or durvalumab in combination with any other approved or 
investigational anticancer agents, in a parent clinical study. Patients enrolled on a control arm in 
a parent study are not eligible.   
At enrollment, informed consent to participate in the study will be obtained from all patients, and 
eligible p
atients will be enrolled in Cohorts 1, 2 or 3, according to their treatment status. There 
are 2 consent forms that will be signed by the patient based on whether the patient is on 
treatment or starting retreatment (treatment informed consent form [ICF]) or off treatment 
(follow -up ICF). All patients in Cohort 1 must sign the treatment ICF. The follow-up ICF will be 
used for patients who enroll in Cohort 3. Cohort 2 patients who will be eligible for future 
retreatment with durvalumab must sign the follow -up ICF at enrollment, then must agree to 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 36 reconsenting under the treatment ICF to start retreatment, and must meet the eligibility 
criteria detailed in Sections 5.1 and 5.2.  
• Cohort 1: includes patients who received durvalumab monotherapy or durvalumab
combination therapy under the p
arent clinical study (including those undergoing
retreatment per the parent study) who have not clinically progressed and who are
eligible to continue durvalumab treatment after completing dosing of all other
anticancer agents, including other investigational agents, which are a formalcomponent of the parent study. If a patient was already retreated with durvalumab in
the parent clinical study and has not progressed while on treatment, then they would be
potentially eligible to enter Cohort 1; a combination treatment course initiated in theparent clinical study must be completed prior to study entry.
• Cohort 2: includes patients who completed durvalumab monothe rapy or in
combination with any ot he
r approved or investigational anticancer agents in a parent
study, without confirmed PD during the period of treatment, and who are potentially
eligible for retreatment with durvalumab. The patient should not have receiv ed any
other approved or investigational anticancer agents since completion of durvalumab
treatment. Patients who completed the prespecified duration of treatment with
durvalumab in a parent clinical study, who received clinical benefit and then
subsequently experienced confirmed PD after completion of planned treatment, will bepermitted to restart durvalumab treatment provided they meet the eligibility criteria.  If
a patient was already retreated with durvalumab in the parent clinical study andretreatment has ended, they are no longer eligible for retreatment in this study.
• Cohort 3: includes patients previously treated with durvalumab monotherapy or in
combination with any other appr ov
ed or investigational anticancer agents who are no
longer re ceiving durvalumab and are not eligible to receive retreatment.
Prospective approval of protoc ol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions , is not permitted. 
Each patient should meet all of the inclusio n criteria and none of the exclusion criteria for this 
study, to be assigned to a study cohort. Under no circumstances can there be exceptions to this 
rule. Patients who do not meet the entry requirements are screen failures, refer to Section 5.4 . 
For procedures for withdrawal of incorrectly enrolled patients see Section 7.3. 
5.1 Inclusion criteria  
Patients are eligible to be included in the study only if all of the following inclusion criteria and 
none of the exclusion criteria apply: 
General inclusion criteria for all patients:  
1. Patient must be 18 years or older, at the time of signing the ICF. For subjects aged <20
years and enrolled in Japan, a
 written ICF should be obtained from the subject and his

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 37 or her legally acceptable representative.  
2. Patient received durvalumab monotherap y and/or  durvalumab containing combination
in an AstraZeneca/MedImmune -sponsored parent clinical study that is approved for
enrollment into this study.
3. Patients who received durvalumab in combination with any other approved or
investi
gational anticancer ag ents in the parent clinical study must have completed or
discontinued all other anticancer therapy (beyond durvalumab regimen).
4. Patient must be willing and able to provide written informed consent and to comply
with sc
heduled visits and other study procedures.
Additional inclusion criteria for patients entering Cohort 1: 
5. Currently receiving durvalumab monotherapy (this includes patients enrolled in
durvalu
mab combinations who have completed or discontinued all other anticancer
therapy combined with durvalum ab in the parent clinical study, and are now receiving
durvalumab monotherapy), and is currently benefiting from treatment withdurvalumab therapy, as determined by the Investigator.
Additional inclusion criteria for patients entering Cohort 1 and Cohort 2 : 
6. Adequa
te organ function as defined below:
(a)Serum bilirubin ≤1.5 × the upper limit of normal (ULN). This will not apply to
patien
ts with confirmed Gilbert’s syndrome, who will be allowed in consultation
with their physician.
(b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
≤2.5 ×  U
LN; for patients with hepatic metastases, ALT and AST ≤5 × ULN.
(c) Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min as
determ
ined by Cockcroft -Gault (using actual bod y WT)
   Males:  
Creatinine CL = Weight (kg) × (140 – Age)  
(mL/min)        72 × serum creatinine (mg/dL)  
Females:  
Creati
nine CL = Weight (kg) × (140 – Age)  ×  0.85 
(mL/min)       72 × serum creatinine (mg/dL)  
7. Evidence of postmenopausal status or negative urinary or serum pregnancy test for
female p
remenopausal patients. Women will be considered postmenopausal if they
have been amenorrheic for 12 months without an alternative medical cause. Thefollowing age -specific requirements apply:

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 38 (a)Women <50 years of age would be considered postmenopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have lu teinizing hormone and follicle-stimulating hormone
levels in the postmenopausal range for the institution.
(b)Women ≥50 years of age would be considered postmenopausal if they have beenamenor
rheic for 12 months or more following cessation of all exogenous
hormonal treatments, had radiation -induced menopause with last menses >1 year
ago, had chemotherapy- induced menopause with last menses >1 year ago.
(c)Women who are surgically sterile (eg, bilateral salpingectomy, bilateral
oophorect
omy, or complete hysterectom y) are eligible.
8. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)
perform
ance status (PS) of ≤2 at enrollment
Additional inclusion criteria for retreatment patients in Cohort 2 
9. Received durvalumab in a parent clinical study that  is a pproved to enroll into this
study.
10. Completed the defined treatment duration with durvalumab monotherapy or
durvalum
ab combination therapy in the parent clinical study, as defined below:
(a)Previously benefited from treatment with durvalumab monotherapy or
durvalu
mab combination therapy, as determined by the Investigator.
(b) Has not previously received retreatment with durvalumab monotherapy.
(c)Maintained SD or better (Response Evaluation Criteria in Solid Tumors
versi
on 1.1 [RECIST v1.1]) throughout the period of defined treatment duration,
and has not received any subsequent anticancer therapy.
11. At least 1 lesion that can be accurately measured at baseline as ≥10 mm in the longestdiame 
ter (except lymph nodes which must have a short axis ≥15 mm) with computed
tomography (CT) or magnetic resonance imaging (MRI), and that is suitable for
accurate repeated measurements as per RECIST v1.1 guidelines.
5.2 Exclusion criteria
Patients must not enter the study if any of the following key exclusion criteria are fulfilled : 
1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff an
d/or staff at the study site).
Additional  exclusion criteria for Cohort 1 and Cohort 2: 
2. Currently receiving treatment in another interventional clinical study other than a
paren
t clinical study, or received treatment during the follow -up period before
retreatment (Cohort 2 only).

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 39 3. Experienced an immune- mediated or non-immune- mediated (hematologic and
non-hematologic) toxicity that led to permanent discontinuation of durvalumab in the
parent clinical study.
4. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology
Crite
ria for Adverse Events (CTCAE) Grade ≥2 from previous anticancer therapy with
the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
criteria.
5. Prior treatment with immunotherapy other than durvalumab, or any other approved or
investi
gational anticancer agents other than MedImmune/AstraZeneca’s
investigational immunotherapy molecules administered in the  parent clinical study.
6. Any concurrent chemotherapy, investigational product (IP), biologic or hormonal
therapy 
for cancer treatment. Concurrent use of hormonal therapy for
non-cancer -related conditions (eg, hormone replacement therapy) is acceptable.
7. Active or p rior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [eg, colitis or Crohn’s disease], diverticulitis [with theexception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, orWegener syndro me [granulomatosis with polyangiitis, Graves’ disease, rheumatoid
arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
(a)Patients with vitiligo or alopecia.
(b)Patie
nts with hypothyroidism (eg, following Hashimoto syndrome) stable on
hormone r
eplacement.
(c)Any chronic skin condition that does not require systemic therapy.
(d)Pati
ents without active disease in the last 5 years may be included but only after
consult
ation with the Study Physician.
(e) Patients with celiac disease controlled by diet alone.
8. History of allogenic organ transplantation.
9. Uncontrolled intercurrent illness, including but not limited to, ongoing or active
infection
, symptomatic congestive heart failu re, uncontrolled hypertension, unstable
angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic GI
conditions associated with diarrhea, or psychiatric illness/social situations that wouldlimit compliance with study requirement, subst antially increase risk of incurring AEs
or compromise the ability of the patient to give written informed consent.
10. Documented active infection including tuberculosis (clinical evaluation that includesclin
ical history, physical examination and radiographic findings, and tuberculosis
testing in line with local practice), hepatitis B virus (HBV) (known positive HBVsurface antigen [HbsAg] result), hepatitis C virus (HCV), or human immunodeficiencyvirus (HIV) (positive HIV 1/2 antibodies). Patients with a past or resolved HBVinfection (defined as the presence of hepatitis B core antibody and absence of HbsAg)are eligible. Patients positive for HCV antibody are eligible only if polymerase chainreaction is negative for HCV RNA. Prior HIV and HBV/HCV testing from the parent

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 40 clinical study is acceptable documentation and patients will not need to undergo an 
additional testing prior to Cohort 1 enrollment in this study. For Cohort 2 patients, prior HIV testing from the parent clinical study is acceptable document ation and 
patients will not need to undergo an additional test prior to retreatment. However, patients will require retesting for HbsAg and HCV within the 28 -day window prior to 
retreatment.  
11. Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug
in the p r
esent study. Note: Patients, if enrolled, should not receive live vaccine while
receiving study drug and up to 90 days after the last dose of study drug.
12. Female patients who are pregnant or breastfeeding, or male or female p atien ts of
reproductive potential who are not willing to employ effective birth control fromscreening to 90 days after the last dose of durvalumab monotherapy or 180 days afterthe last dose of durvalumab + tremelimumab combination.
−Highly effective meth ods of
  contraception are defined as one that results in a low
failure rate (eg, less than 1% per year) when used consistently and correctly. Note
that some contraception methods are not considered highly effective (eg, male orfemale condom with or without spermicide; female cap, diaphragm, or spongewith or without spermicide; non -copper containing intrauterine device;
progestogen-only oral hormonal contraceptive pills where inhibition of ovulationis not the primary mode of action [excluding Cerazette/des ogestrel which is
considered highly effective]; and triphasic combined oral contraceptive pills).
−For patients randomized to receive SoC treatment in parent protocols, follow thelocal p
rescribing information relating to contraception, the time limit for s uch
precautions, and any additional restrictions for agents in the SoC treatmentregimen.
13. Diagnosis of a new primary malignancy since enrollment into the parent clinical study,
with the 
 exception of adequately treated non- melanomatous skin cancer and carci noma
in situ with no evidence of disease.
14. Must not have required the use of additional immunosuppression other than
cortico
steroids for the management of an AE >Grade 1, have not experienced
recurrence of an AE if re -challenged, and not currently require m aintenance doses of
>10 mg prednisone or equivalent per day.
15. Known allergy or hypersensitivity to any of the study drugs or any of the study drug
excipien
ts.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 41 5.3 Lifestyle restrictions 
The following restrictions apply while the patient is receiving durvalumab and for the specified 
times before and after:  
1. Female patient of childbearing p otential
−Female patients of childbearing potential who are not abstinent and intend to be  
sexually active with a non-st erilized male partner, must use at least 1 highly  
effective method of contraception (Table 5) from the time o f screening throughout  
the total duration of the drug treatment and the drug washout period (180 days 
after the last dose of durvalumab + tremelimumab combination therapy or 90 days 
after the last dose of durvalumab monotherapy). Non-st erilized male partners of a  
female patient of childbearing potential must use a male condom plus spermicide  
throughout this period. Cessation of birth control after this point should be 
discussed with a responsible physician. Periodic abstinence, the rhythm method, 
and the withdrawal method ar e not acceptable methods of contraception. Female  
patients should refrain from breastfeeding throughout this period.
−Pregnancy testing will be performed according to the schedule of activities (SoA)
(Table 1, Table 2, and Table 3).
2. Male patients with a female partner of  child bearing potential
−Non-st erilized male patients who are not abstinent and intend to be sexually active  
with a female partner of childbearing potential, must use a male condom plus 
spermicide from the time of screening throughout the total duration of the drug  
treatment and the drug washout period (180 days after the last dose of durvalumab
+ tremelimumab combination therapy or 90 days after the last dose of durvalumab  
monotherapy). Periodic abstinence, the rhythm method, and the withdrawal 
method are not acceptable methods of contraception. Male patients should refrain  
from sperm donation throughout this period.
−Female partners (of childbearing potential) of male patients must also use a highly 
effective method of contraception throughout this period (Table 5).
Please note, females o f chil dbe aring potential are defined as those who are not surgically sterile 
(ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or 
postmenopausal.  
Women will be considered postmenopausal if they have been amenorrheic for 12 months without 
an alte
rnative medical cause. The following age- specific requirements apply:  
• Women <50  years of age would be considered postmenopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments an d if they have luteinizing hormone and follicle-stimulating hormone
levels in the postmenopausal range for the institution.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 42 • Women ≥50 years of age would be considered postmenopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonaltreatments, had radiation -induced menopause with last menses >1 year ago, had
chemotherapy-induced menopause with last menses >1 year ago.
• Women w
 ho are surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy,
or com plete hysterectomy) are eligible.
Highly effective methods of contraception defined as one that results in a low failure rate (ie,  less 
tha
n 1% per year) when used consistently and correctly are described in Table 5 . Note that some 
contrac
eption methods are not considered highly effective (eg, male or female condom with or 
without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper 
containing intrauterine device; progestogen- only oral hormonal contraceptive pills where 
inhibition of ovulation is not the primary mode of action [excluding Cerazette/desogestrel which 
is considered highly effective]; and triphasic combined oral c ontraceptive pills).  
Table 5  Highly effe ctive methods of contraception (<1% failure rate)  
Barrier/intrauterine 
methods  Hormonal methods  
•Copper T intrauterinedevice
•Levonorgestrel -releasing
intrauterine system (eg,Mirena®)
a•Implants: Etonogestrel-releasing implants (eg, Implanon® orNorplant®)
•Intravaginal Devices: Ethinylestradiol/etonogestrel -releasing
intravaginal devices (eg, NuvaRing®)
•Injection: Medroxyprogesterone injection (eg,Depo -Provera®)
•Combined Pill: Normal and low dose combined oralcontraceptive pill
•Patch: Norelgestromin/ethinylestradiol-releasing transdermalsystem (eg, Ortho Evra®)
•Minipill: Progesterone -based oral contraceptive pill using
desogestrel: Cerazette® is currently the only highly effec tive
progesterone -based pill
aThis is also considered a hormonal method.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 44 Table 6  Study treatment  
Treatment  
Study treatment 
name:  Durvalumab (MEDI4736)  
Dosage formulation: 500-mg vial solution for infusion after dilution, 50 mg/mL
Ro
ute of 
administr
ation: Intravenous (IV)  
Dose:  1500 mg 
Dosing instruct
ions:  A dose of 1500 mg will be delivered through an IV administration set with a 
0.2 μm o
r 0.22  μm filter. If a patient’s weight falls to 30 kg or below (≤30 kg), 
then the patient should receive weight -based dosing equivalent to 20 mg/kg of 
durvalumab q4w until weight improves to above 30 kg (>30 kg).  
Packaging and 
labeling:  St udy drug will be provided in vials. Each vial will be labeled in accordance with 
Good Manuf
acturing Practice Annex 13 and per country regulatory requirement.a 
Frequency:  Every 4 weeks 
Manufacturer:  MedImmune 
Provider: AstraZeneca  
aLabel text prepared for durvalumab (MEDI4736) will show the product name as “MEDI4736” or “durvalumab 
(MEDI4736)” depending upon the agreed product name used in the approved study master label document. All 
naming conventions are correct during this transi tional period.  
6.1.1.1 Durvalumab (MEDI4736) 
Durvalumab (MEDI4736) will be supplied by AstraZeneca as a 500-mg vial solution for infusion 
after
 dilution. The solution contains 50 mg/mL durvalumab (MEDI4736), 26 mM 
histidine/histidine -hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) 
polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The nominal fill volume is 10.0 mL. IP vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Drug product should be kept in original packaging until use to prevent prolonged light exposure. 
Preparation of durvalumab (MEDI4736) doses for administration with an IV bag 
The dose of durvalumab (MEDI4736) for administration must be prepared by the Investigator’s 
or site’
s designated IP manager using aseptic technique. Total time from needle puncture of the 
durvalumab (MEDI4736) vial to the start of administration should not exceed:  
• 24 hours at 2°C to 8°C (36°F to 46°F)

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 45 • 4 hours at room temperature
A dose of 1500 mg will be administered using an IV bag containing 0.9% (w/v) saline or 5% 
(w/v) de
xtrose, with a final durvalumab (MEDI4736) concentration ranging from 1 to 15 mg/mL 
and delivered through an IV administration set with a 0.2- or 0.22- μm filter.  Add 30.0 mL of 
durvalumab (MEDI4736) (ie, 1500 mg of durvalumab [MEDI4736]) to the IV bag. The IV bag 
size should be selected such that the final concentration is within 1 to 15 mg/mL. Mix the bag by 
gently inverting to ensure homogeneity of the dose in the bag.  
If patient weight falls to ≤30 kg, WT -based dos ing at 20 mg/kg will be administered using an IV 
bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab (MEDI4736) 
concentration ranging from 1 to 15 mg/mL and delivered through an IV administration set with a 0.2- or 0.22- μm filter.  
Standard infusion time is one hour; however, if there are interruptions during the infusion, the total a
llowed infusion time should not exceed 8 hours at room temperature.  
Do not co-administer other drugs through the same infusion line. 
The IV line will be flushed with a volume of IV diluent equal to the priming volume of the 
infusio
n set used, after the contents of the IV bag are fully administered, or complete the infusion 
according to institutional policy to ensure the full dose is administered.  
If either preparation time or infusion time exceeds the time limits, a new dose must be prepared 
from new
 vials. Durvalumab (MEDI4736) does not contain preservatives and any unused portion 
must be discarded.  
6.1.2 Dose and treatment regimen  
6.1.2.1 Durv
alumab (MEDI4736) monotherapy  
Pati
ents who receive durvalumab monotherapy treatment (Cohort 1) or durvalumab monotherapy 
retreat
ment (Cohort 2) will receive 1500  mg durvalumab via IV infusion q4w, until PD is 
determined by the Investigator following RECIST v1.1, unless there is unacceptable toxicity, 
withdrawal of consent, or another discontinuation criterion is met. See  Figure 2 (P lease note, if a 
patien
t’s weight falls to 30  kg or below, the patient should receive WT-based dosing equivalent 
to 20 mg/kg of durvalumab q4w after consultation between the Investigator and Study Physician, until the weight improves to >30 kg).  
The standard infusion time is 1 hour; however, if there are interruptions during infusion, the total allowe
d time should not exceed 8 hours at room temperature. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001
CONFIDENTIAL AND PROPRIETARY 46Figure 2 Durvalumab monotherapy dosing schedule
Q4W every 4 weeks.
6.1.3 Durat ion of treatment and criteria for treatment through progression and for 
retreatment
All durvalumab t reatment will be a dministered b eginning on Day 1 (C ohort 1) or Day 1 
retreatment (Cohort 2), until progression as determined by the Investigator using RECIST v1.1 
(refer to Appendix C), unless there is unacceptable toxicity, withdrawal of consent, or another 
discontinuation  criterion  is me t.
Patients r eceiving durvalumab who experience PD and, in the Investigator’s opinion, c ontinue to 
receive  benefit from their assigned tr eatment may  continue to receive  durvalumab fo r as long  as
they me et specific  clinical criteria and are de riving clinical benefit in the opinion of the 
Investigator. For all patients who are treated through PD, the I nvestigator should ensure patients 
still meet all of  the inclusion  criteria and none  ofthe exclusion c riteria fo r this study and obtain
additional i nformed consent for continuation  of treatment. T he treatment ICF  will specify th at 
treatment beyond  initial evidence o f PD is not  thestandard o f care and  that alternative tre atment 
options, e ither locally licensed t reatments or o ther clinical trials,  are potentially av ailable for this 
patient population. 
Patients w ith rapidtumor progression or  with s ymptomatic p rogression,  that require u rgent 
medical intervention  (eg, central nervous  system metastasis,  respiratory failure due to tumor 
compression, or spinal cord compression) will not be eligible for continuing durvalumab (refer 
to Appendix C). 
For all patients who are continuously treated through progression and for patients who are 
restarting durvalumab monotherapy, the Investigator should ensure t hat: 
• The patient does not have any significant, unacceptable, or irreversible toxicities, that
indicate continuing treatment will not further benefit the patient. The patient ma y not
have experienced a toxicity that required permanent discontinuation of study
treatment.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 47 • There is absence of clinical symptoms or signs indicating clinically significant disease  
progression accompanied by a decline in WHO/ECOG PS to >2
• There is absence of rapid disease progression or threat to vital organs or critical  
anatomical sites (eg, central nervous system metastasis, respiratory failure due to  
tumor compression, or spinal cord compression) requiring urgent alternative medical  
intervention
• The patient still fulfills the eligibility criteria for this study (see Sections 5.1 and 5.2). 
Patients must also agree to reconsenting to restart durvalumab monotherapy.
• The patient has not received an intervening sy stemic anticancer therapy after their  
assigned treatment discontinuation from the parent study
The patient has had a retreatment baseline tumor assessment within a maximum of 28 days prior 
to res
tarting durval umab (Cohort 2). In Cohort 1, patients will continue with durvalumab 
monotherapy at 1500 mg q4w until disease progression as confirmed by the Investigator 
following RECIST v1.1.  
During the retreatment period in Cohort 2, eligible patients will resume durv aluma b dosing at 
1500 mg q4w until disease progression as determined by the Investigator following 
RECIST  v1.1.  
Patients who the Investigator determines may not continue treatment after PD will be followed up for OS , a 
nd are no longer eligible for retreat ment.  Patients who have discontinued treatment 
due to toxicity or symptomatic deterioration, or who have commenced subsequent anticancer 
therapy, will be followed for OS until withdrawal of consent or death. Upon discontinuation of 
durvalumab, patients may  receive any subsequent anticancer therapy at the discretion of the 
Investigator.  
6.1.4 Storage 
The Inve
stigator, or an approved representative (eg, pharmacist), will ensure that all IP is stored 
in a secured
 area, in refrigerated temperatures (2°C to 8°C) and in accordance with applicable 
regulatory requirements. A temperature log will be used to record the temperature of the storage area. Temperature excursions outside the permissible range listed in the clinical supply packaging are to be reported to the monitor upon detection. A calibrated temperature monitoring 
device will be used to record the temperature conditions in the drug storage facility. Storage 
conditions stated in the IB may be superseded by the label storage.  
6.2 Measures to minimize bias: randomization and blinding  
Not applicable. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 48 6.3 Treatment compliance 
Study measures will be taken t o ensure to document durvalumab treatment compliance, with 
dates of administration, dosing information, a nd any safety events related to medication 
administration will be captured in the study database. Collection and reporting of durvalumab 
overdoses are summarized in Section 8.4.3. 
The administration  of all IP s should be  recorded in the  appropriate sections  of the electronic c ase 
report form (eCRF). 
Any change from the dos ing schedule, dose de lays/interruptions, and dose discontinuations 
should be recorded i n eCRF. Dose reductions are not allowed. 
The IP S torage Manager is responsible for managing the IP from receipt by the study site until 
the destruction or return of all unus ed IP. 
6.4 Concomitant therapy  
The Investigator must be informed as soon as possible about any medication taken from the time 
of enrollment until the end of the durvalumab treatment, including the 90-day follow-up period 
following the last dose of study drug. This applies only for patie nts receiving durvalumab 
through 90 days after the last dose, and does not apply to patients from Cohort 2 who are not 
retreated and patients in Cohort 3. No restrictions apply to patients off treatment who are over 
90 days from their last dose of durvalumab.  
Any medication or vaccine including over- the-coun ter or prescription medicines, vitamins, 
and/or herbal supplements that the patient is receiving at the time of enrollment or receives 
during the study must be recorded along with: 
• Reason for use
• Dates of administration including start and end dates
• Dosage information including dose, unit, and frequency
Pati
ents must be instructed not to take any medications, including over- the-counte r products, 
without first consulting with the Investigator.  
Restricted,  prohibit ed, and permitted concomitant medications are described in the following 
tables. Refer also to the Dosing Modification and Toxicity Management Guidelines (see 
Annex 1).  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 49 Table 7  Prohibited concomitant medications  
Prohibite d medications/class of drug:  Usage:  
Cohort 1 and retreated patients in Cohort 2, only  
Any investigational anticancer therapy 
other than those under investigation in this study  Should not be given concomitantly while the patient is on study tr
eatment 
Monoclonal antibodies against CTLA -4, 
PD-1, or PD-L1 other than those under 
investigation in this study  Should not be given concomitantly while the patient is on study tre
atment  
Any concurrent chemotherapy, radiotherapy, immunotherapy, or biolo gic or hormonal therapy for cancer 
treatment other than those under investigation in this study  Should not be given concomitantly while the patient is on study tre
atment. (Concurrent use of hormones for 
non-cancer -related conditions [eg,  insulin for diabet es and 
hormone replacement therapy] is acceptable. Local treatment of isolated lesions, excluding target lesions, for 
palliative intent is acceptable [eg, by local surgery or 
radiotherapy]. ) 
Immunosuppressive medications including, but not limited to, sys temic 
corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent, 
methotrexate, azathioprine, and tumor necrosis factor-α blockers  Should not be given concomitantly or used for premedi
cation prior to the immuno-oncology infusions. The 
following are allowed exceptions:  
•Use of immunosuppressive medications for themanagement of IP -related AEs
•Use in patients with contrast allergies
•In addition, use of inhaled, topical, and intranasalcorticosteroids is permitted
A temporary period of steroids will be allowed if clinically 
indicat
ed and considered to be essential for the 
management of non-immunotherapy related events 
experienced by the patient (eg, chronic obstructive 
pulmonary disease, radiation, nausea, etc).  
Herbal and natural remedies which  may 
have immune-modulating effects Should not be given concomitantly unless agreed by the Sponsor.  
Cohorts 1 to 3 
Live attenuated vaccines Should not be given within 30 days prior to the first dose of IP in the
 present study and through 90 days after the last 
dose of IP.  
Drugs with laxative properties and herbal or natural remedies for constipation  Should be used with caution through 90 days after
  the last 
dose of tremelimumab during the study, if the patient 
received combination therapy of tremelimumab and durvalumab in the parent clinical study.  
Sunitinib  Should not be given concomitantly or through 90 days after 
the last d
ose of tremelimumab (acute renal failure has been 
reported with combination therapy of tremelimumab and 
sunitinib)  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 50 Prohibite d medications/class of drug:  Usage:  
Epider mal growth factor receptor 
(EGFR) tyrosine kinase inhibitors 
(TKIs)  Should not be given concomitantly. 
Should be used with caution in the 90 days post last dose of 
durvaluma
b.  
Increased incidences of pneumonitis (with third generation EGFR TKI
s) and increased incidence of transaminase 
increases (with first generation EGFR TKIs) has been reported when durvalumab has been given concomitantly.  
AE adverse event; CTL cytotoxic T -lymphocyte -associated; EGFR epidermal growth factor receptor; IP 
investigational product; TKI tyrosine kinase inhibitor; PD programmed death  
Table 8  Supportiv e medications  
Supportive medications/class of drug:  Usage:  
Concomitant medications or treatments (eg,  acetaminophen or 
diphenhydramine) deemed necessary to provide adequate prophylactic or 
supportive care, except for those medications identified as “prohibited,” as 
listed above  To be administered as prescrib
ed by  the 
Investigator  
Best supportive care (including antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control, and pain management [including palliative radiotherapy to non- target lesions, etc])  Should be used, when necess ary
, for 
all patients  
Inactivated viruses, such as those in the influenza vaccine Permitted  
6.4.1 Other concomitant treatment  
Medication other than that described above, which is considered necessary for the patient’s 
safet
y and wellbeing, may be given at the discretion of the Investigator and recorded in the 
appropriate sections of the case report form (CRF).  
6.4.2 Durvalumab drug -drug int eractions  
Currently, there is no information to date on drug- drug in teractions with durvalumab either 
preclinically or in patien ts. As durvalumab is a mAb and therefore a protein, it will be degraded 
to small peptides and amino acids and will be eliminated by renal and reticuloendothelial CL. It is therefore not expected that durvalumab will induce or inhibit the major drug metabol izing 
cytochrome P450 pathways. As a result, there are no expected PK drug-drug interactions. The 
MOA of durvalumab involves binding to PD-L1, and therefore significant pharmacodynamic 
drug interactions with the commonly administered concomitant medication s are not expected. 
Despite this,  appropriate clinical monitoring in all of the planned clinical studies will be 
conducted to evaluate any potential drug- drug interactions.  
6.4.3 Rescue medication  
As a re
sult of immune -mediated  adverse events (imAEs) that could potentially be experienced by 
patients on durvalumab, steroids and other immunosuppressant rescue medication has to be made 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 51 available to this patient population. The 2 products that fall into the category of 
immunosuppressants are infliximab (eg,  for colit is) and mycophenolate (eg, for hepatitis). 
AstraZeneca supply chain will be responsible for sourcing these 2 rescue medications to the sites if local regulations prevent the use of infliximab and mycophenolate in this indication, as they are considered off- label for management of immunotherapy -related toxicities. These rescue 
medications must be receipted and controlled by the pharmacist and stored according to the labeled storage conditions, with temperature excursions reported accordingly by the pharmacist. If required for use as a result of an imAE, then the interactive voice response system 
(IVRS)/interactive web response system (IWRS) will provide to the pharmacists the kit 
identification number to be allocated to the patient at the time.  
6.5 Dose modification  
Dose delays are permitted for immuno -oncology therapy (see Dosing Modification and Toxicity 
Management Guidelines in Annex 1). However, dose reduction is not permitted .  
6.6 Treatment after the end of the study 
AstraZeneca w ill continue to s upply durvaluma b after completion of this study, for as long as the 
patient is receiving clinical benefit in the opinion of the Investigator, o r until the participant 
meets a discontinuation criteria as d efined in Section 7.1.  
For patients continuing  to receive  durvalumab t reatment following  the final DCO a nd database 
closure , the procedures defined in th e SoA will be  limited. I t is recommended that the 
participant s continue  the sche duled s ite visits and  Investigators moni tor the patient’s safety 
laboratory results p eriodically dur ing treatment with d urvalumab in o rder to ma nage AEs in 
accordance with the durvalumab Dosing Modification and T oxicity Management Guidelines 
(see Annex 1), and as  described in Section 8.3.14. 
In the  event that produc t development reaches a p oint where alternativ e product supply options 
become a vailable , then these a lternative product supply options will be discussed by 
AstraZeneca w ith the  Investigator. A straZeneca w ill work w ith the  Inve stigator  to tr ansition  the 
patient(s) to alternative supply, where possible.  
In the  event that a roll- over or safety e xtension  study is available a t the time of  the final DCO 
and database closure, pa tient(s) currentl y receiving treatment with durvalumab ma y then be 
transitione d to such a study, and the c urrent st udy would reach its end. The roll-over or extension 
study  would e nsure t reatment continuation  with vis it assessments p er its pr otocol, a s applicabl e. 
Any patient who would be e ligible to move to such a study would be given a new informed 
consent, as applicable.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 52 7. DISCONTINUATION OF TREATMENT AND PATIENT
WITHDRAWAL
7.1 Discontinuation of study treatment
An individual patient will not receive any further durvalumab monotherapy if any of the 
following occur in the patient in question: 
• Withdrawal of consent from further treatment with IP. The patient is, at any time, free  
to discontinue treatment, without prejudice to further treatment. A patient who  
discont inues treatment is normally expected to remain in the study for safety and OS  
follow-u p unless they specifically withdraw their consent to  all further participation in  
any study procedures and assessments (see Section 7.3).
• An AE that, in the opinion of the Investigator or AstraZeneca, contraindicates further  
dosing.
• Any AE that meets criteria for discontinuation as defined in the Dosing Modification 
and Toxicity Management Guidelines (see Annex 1) or as defined in the local  
prescribing information for the agent.
• Pregnancy or intent to become pregnant
• Non-compliance with the study protocol that, in the opinion of the Investigator or 
AstraZeneca, warrants withdrawal from treatment with IP (eg, refusal to adhere to  
scheduled visits).
• Initiation of alternative anticancer therapy including another investigational agent
• Disease progression as determined by the Investigator following RECIST v1.1 (refer 
to Appendix C) and Investigator determination that the patient is no longer benefiting  
from treatment with IP.
Upon discontinuation of durvalumab, patients m ay receive any subs equent ant icancer therapy  at 
the discretion of the Investigator and will follow the schedule of activities (SoA)  detailed for 
Cohort 3 for safety and survival follow-up ( Table 3). 
7.1.1 Procedures for discontinuation of study treatment  
Discontinuation  of study  trea tment, fo r any  reason, doe s not  impac t the patient’s pa rticipation  in 
the study. A patient who decides to discontinue IP will always  be asked ab out the reason(s) f or 
discontinuation and the presence of any AE. The patient should continue attending subsequent 
study visits, and data collection should continue according to the study protocol (Table 3). If the 
patient does not agree to continue in-person study visits, a modified follow-up must be arranged 
to ensure the collection of endpoints and safety information. This follow-up could be a telephone 
contact with the  patient (or a pr especified pr eferred me thod of contact, a s an alternative), a 
contact with a re lative or  treating  physician,  or information  from medica l records. T he approach 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 53 taken shou ld be  recorded in t he medical r ecords , and the preferre d method of contact will be 
recorded in t he patient contac t module for  this s tudy.  A patient that agrees to modi fied follow -up 
is not considered to have withdraw n consent or to have withdrawn from the study. 
Patients w ho are pe rmanently d iscontinued from furthe r receipt of IP, r egardless of  the reason,  
will be identified as having permanently discontinued treatment. Patients who have permanently 
discontinued treatment will enter follow-u p (see Section 1.1). 
All patients will be  followed for  survival with c ontac t approximately e very 3 mont hs (±2 w eeks) 
beginning 90 days after the l ast dose of the study drug until the end of the study.  
Patients who decline to retur n to the site for evaluations should be contacted by telephone ( or a 
prespecified preferred method  of contact) as indicated in the SoAs as an al ternative.  
Patients who have permanently discontinue d fro m further receipt  of IP w ill ne ed to be  
discontinued from  the IVRS/IWRS. 
7.2 Lost to follow -up 
Patients will be considered lost to follow -up only if no contact has been established after 
2 consecutive failed contacts. A “contact” is defined as 3 attempts of the preferred method of 
contact recorded in the patient contact module, and then 3 attempts of the preferred alternative contact designee ±2 weeks from the targeted date (set by the interval shown in the SoAs). At this 
time, the patient will be  flagged as lost to follow -up in the electronic data capture (EDC; 
2 consecutive time points with no patient or alternative contact), whereby the Investigator would 
be requested to review the patient record and update the patient status, if known. Patients who 
refuse to continue participation in the study, including telephone contact (or a prespecified 
preferred method of contact, as an alternative), should be documented as “withdrawal of consent” rather than “lost to follow -up.” Investigators should docume nt attempts to re -establish 
contact with missing patients throughout the study period. If contact with a missing patient is re-established, the patient should not be considered lost to follow-up and evaluations should 
resume according to the protocol.  
In order to support key endpoints of OS analyses, the survival status of all patients in the full analys i
s and the safety analysis sets should be re -checked, this includes those patients who 
withdrew consent or are classified as “lost to follow -up.” 
• Lost to follow -up – sit e personnel should check hospital records, the patients’ current
physician, and a publicly available death registry (if available) to obtain a currentsurvival status. (The applicable CRF modules will be updated.)
• In the event that the patient has actively withdrawn consent to the processing of theirperson
al data, the survival status of the patient can be obtained by site personnel from
publicly available death registries (if available) where it is possible to do so under
applicable local laws to obtain a current survival status. (The applicable CRF modules
will be updated.)

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 54 7.3 Withdrawal from the study  
Patients are free to withdraw from the study at any time (IP and assessments) without prejudice 
to further treatment.  
Patients who withdraw conse nt for furth er participation in the study will not receive any further 
IP or further study observation, with the exception of follow-up for survival, which will continue until the end of the study unless the patient has expressly withdrawn their consent to  survival 
follow -up. Note that the patient may be offered additional tests or tapering of treatment to 
withdraw safely.  
A patient who withdraws consent will always be asked about the reason(s) for withdrawal and 
the pres
ence of any AE. The Investigator wil l follow  up AEs outside of the clinical study.  
If a patient withdraws consent, they will be specifically asked if they are withdrawing consent to:  
• All further participation in the study including any further follow  up (eg, sur vival
contact telephone calls)
8. STUD Y ASSESSMENTS AND PR OCEDURES
Data collection  and f requency are summarized b y each of  the 3 cohorts below: 
In Cohort 1,  all du rvalumab treatment  cycle assessments will o ccur every 4 w eeks until 
confirmed PD, unless unacceptable toxicity, withdrawal of consent, or another discontinuation 
criterion  is met. T he most recent  imaging  results from  the parent clinical study  may be used for  
baseline t umor assessments, provided it was obtained withi n 28 days prior to Day 1, Cycle 1. 
Tumor assessments throughout all cycles w ill be  performed according to RECIST v1. 1, as 
determine d by the Investigator (at least every 12 weeks) until withdrawal of consent, 
progression, or death. T he patients will co ntinue their durvalumab treatment and all cycle 
assessments every 4 weeks ±3 days unless dosing needs to be held for toxicity reasons (Table 1). 
Cohort 2 follow- up prior to re treatment with dur valumab monotherapy follows th e SoA for  
Cohort 3, while patients who undergo retreatment begin the assessment as per the SoA for 
patients in Cohort 1. During the follow-up of patients before retreatment , they will undergo 
assessments for  vital signs, conc omitant  medications, laboratory safety and A E/SAE at 30  days 
(±3 da ys), 60 days (±7 days), and 90 days (±7 days) since the last dose of study dr ug. The 
assessment for concomitant medications will be collected throughout 90 days post durvalumab 
discontinuation. The survival status for these patients will be  collected ev ery 3 m onths 
(±2 weeks) beginning 90 days a fter the l ast dose of the study drug and tumor assessments will be 
performed accordi ng to the Investigator’s standard practice u ntil withdrawal of consent, 
progression, or death. F or those tha t start retreatment, pa tients will continue the ir durvalumab 
monotherapy and all cycle assessments every 4 weeks ±3 days unless dosing needs to be held for 
toxicity reasons. While on r etreatment, tumor assessments and disease progression will be 
determined by the Investigator following RECIST v1.1 (Table 2).  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 55 Cohort 3 includes safety and survival follow-up only for patients previously treated with 
durvalumab monotherapy or durvalumab in combination with any other approved or 
investigational anticancer agents who are no longer receiving durvalumab and are not eligible to 
receive retreatment. The patients would undergo assessments as per the SoA ( Table  3). 
The Investigator will obtain informed consent of study procedures at baseline/enrollment from 
eligible s
tudy patients. The Investigator will ensure that data are recorded on the eCRFs. The 
EDC system will be used for data collection and query handling. The Investigator will ensure the 
accuracy and completeness of eCRFs, including timeliness of the data recorded and of the 
provision of ans wers to data queries according to the Clinical Study Agreement. The Investigator 
will sign the completed eCRFs. A copy of the completed eCRFs will be archived at the study 
site. 
Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence or awa r 
eness to determine if the patient should continue or discontinue study treatment. 
Adherence to the study design requirements, including those specified in the SoA, is essential 
and requir
ed for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential patients 
meet all 
eligibility criteria. The Investigator will maintain an enrollment log to record details of 
all patients screened and to confirm eligibility or record reasons for non -enrollment, as 
applicable.  
Procedures conducted as part of the patient’s routine clinical management (eg, blood count and 
imagin
g assessments)  and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol -specified criteria and were 
performed within the time frame defined in the SoA.  
The amount of blood collected from each patient over the duration of the study, including any 
extra assess
ments that may be required, will be dependent on the local laborat ory requirements. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.  
8.1 Safety assessments 
Planned time points for all safety assessments are provided in  the SoA (see Section 1.1). Any 
assessments which are relevant  to preservation  of patient sa fety, as scheduled in the parent  
clinical study, will be conducted and followed up as per the SoA for this study. 
The safety and tolerability of durvalumab monotherapy up until 90 days after the last dose of 
study  in all patients will be  assessed as a primary obj ective, a s described i n Section  3. After 
90 days of the last dose of durvalumab, Investigators will be instructed t o report any AE/SAE 
according to the standard pharmacovigilance process outside of the remit for this study. 
Additiona l safety c ollection and reporting guidelines for this study will be provide d in a Safety 
Handling Plan. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 56 8.1.1 Clinical safety laboratory assessments 
Blood and urine samples for determination of clinical chemistry, hematology, and pregnancy will 
be taken a t
 the times indicated in the SoA an d as clinically indicated (see Section 1.1).  
Clinical laboratory safety tests, including serum pregnancy tests, will be performed in a licensed 
clinical laboratory according to local standard procedures. Sample tubes and sample sizes may vary depending on the laboratory method used and routine practice at the site. Pregnancy tests may 
be performed at the site using a licensed test (urine or serum pregnancy test). Abnormal c linically 
significant laboratory results should be repeated as soon as possible (preferably within 24 to 48 hours). 
Additional safety samples may be collected if clinically indicated at the discretion of the 
Investigator. The date, time of collection, and results (values, units, and reference ranges) will be 
recorded on the appropriate eCRF. 
The laboratory variables to be measured are presented in Table 9 (clinical chemistry) and Table 10 
(hematology).  
The following laboratory variables will be measured: 
Table 9  Clinical chemistry 
Albumin  Lipaseb 
Alkaline phosphatase Magnesiumc 
ALTa Potassium  
Amylaseb Sodium 
ASTa Total bilirubina 
Bicarbonatec Total protein  
Calcium TSHe 
Chloridec T3 freef (reflex)  
Creatinined T4 freef (reflex)  
Gamma glutamyltransferasec Urea or blood urea nitrogen, depending on local practice  
Glucose  
Lactate dehydrogenase  
a.Tests for ALT, AST, alkaline phosphatase, and total bilirubin must be conducted and assessed concurrently. If
total bilirubin is ≥2 × upper limit of normal (and no evidence of Gilbert’s syndrome), then fractionate into
direct and indirect bilirubin.
b.It is prefera ble that both amylase and lipase parameters are assessed. For sites where only 1 of these parameters
is routinely measured, either lipase or amylase is acceptable.
c. Bicarbonate (where available), chloride, creatinine clearance, gamma glutamyltransferase,  magnesium, testing
is to be performed at baseline, on Day  1 (unless all screening laboratory clinical chemistry assessments are
performed within 3 days prior to Day 1), and if clinically indicated.
d. Creatinine clearance will be calculated by data management using Cockcroft -Gault (using actual body weight).
e. If TSH is measured within 14 days prior to Day 1 (first infusion day), it does not need to be repeated at Day 1. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 57 f. Free T3 or free T4 will only be measured if TSH is abnormal or if there is a clin ical suspicion of an AE related
to the endocrine system.
ALT alanine aminotransferase; AST  aspa rtate aminotransferase, T3 triiodothyronine; T4 tetraiodothyronine; TSH 
thyroid- stimulating hormone.  
Table 10  Hematology  
Absolute neutrophil counta Absolute lymphocyte counta 
Hemoglobin  Platelet count  
Total white cell count  
a.Can be recorded as absolute counts or as percentages. Absolute counts will be calculated by Data Management
if entered as percentage. Total white cell count therefore has to be provided.
Note: For coagulation parameters, activated partial thromboplastin time and international normalized ratio are to be 
assessed
 at baseline on Day 1 (unless all screening laboratory hematology assessments are pe rformed within 
3 days prior to Day 1), and as clinically indicated.  
If a pa tient shows a n AST or ALT ≥ 3 × ULN t ogether with total bilirubin ≥2 × ULN, re fer to 
Appendix B for further instructions on cases of increases in liver biochemistry and evaluation of 
Hy’s Law ( HL). T hese cases should be  reported as SAEs if, after eva luation,  they meet the 
criteria fo r a H L case or  if any  of the individual liver t est parameters fu lfill any  of the SAE 
criteria.  
All patients should ha ve further chemistry pr ofiles pe rformed a t 30 days (±3 da ys), 2 months 
(±1 w eek), and 3 months (±1 week) after permanent discontinuation of durvalumab ( see the 
SoAs). 
Any clinically significant abnormal laboratory values should be repeate d as clinicall y indicated 
and recorded on the eCRF. Situations in which laboratory safety results should be reported as 
AEs are described  in Section 8.3.7. 
All patients with G rade 3 or 4 laboratory va lues a t the time of  completion  or discontinuation  
from durvalumab mus t have  further tests p erformed unt il the la boratory values ha ve returned to 
Grade 1 or  2, unless these value s are not  likely to improve because of  the underlying  disease. 
8.1.2 Physical examinations  
Physical examinations will b e perf or med acco rding  to the assessment sch edules ( see the SoAs). 
Full phys ical exa minations will i nclude assessme nts of the head, eyes, ears, nose, and throat and 
the respiratory, cardiovascular, GI, urogenital , musculoskeletal, neurological, dermatological, 
hematologic/lymphatic , and endocrine systems . Height will be measured at screening only. 
Targeted ph ysical exa minations are to be utilized by the Investigator on the basis of clinical 
observations and symptomatology. Situations in which physical examination results should be 
reported as AEs are described in  Section 8.3.7.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 58 8.1.3 Vital signs  
Vital signs (blood pressure [BP], pulse, temperature, and respiration rate) will be evaluated 
according to the SoAs. Body weight is also recorded at each visit along with v ital signs. 
First  
infusion of the retreatment 
On the first infusion day, patients receiving durvalumab monotherapy will be monitored and vital 
signs collected/recorded in the eCRF prior to, during, and after infusion of durvalumab as 
presented in the bulleted list below.  
Blood pressure and pulse will be collected from patients receiving durvalumab treatment before, 
during, and after each infusion at the following times (based on a 60-m inute infusion): 
• Prior to the beginning of the infusion (measured once from approximately 30 minutes
befor e
 up to 0 minutes [ie, the beginning of the infusion])
• Approximately 30 minutes during the infusion ( halfw ay through infusion)
• At the end of the infusion (approximately 60 minutes  ±5 minutes)
If the infusi on takes lon ger than 60 minutes, then BP and pulse measurements should follow the 
principles as described above or be taken more f requentl y if clinically indicated. A 1-hour 
observati on peri od is recommende d after the first infusion of durvalumab.  
Subsequent i nfusions 
Blood pressure, pulse , and other vital signs should be measured, collected/recorded i n eCRF 
prior  to the  start of the in fusion.  Patients should b e carefully monitored,  and BP and other vital 
signs should be measured during and post infusion as per institution standard and as clinically 
indicated. Any clinically significant changes in vital signs should be entered onto a n unscheduled 
vital signs CRF page.  
Situations in which vital sign results should be reported as AEs are described in Section  8.3.7. 
For any AEs of infusi on reactions , the vital signs values should be entered into the CRF. 
8.1.4 Early patient review for safety for retreated patients  
Among p at
ients starting retreatment in Cohort 2, it is recommended that patients are contacted 
2 weeks a
fter receiving the first 3 cycles of durvalumab monotherapy (Cycle 1 Day 14, Cycle 2 
Day 14, and Cycle 3 Day 14) of study drug to ensure early identification and management of toxicities.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 59 Review of safety data will be conducted in accordance with AstraZeneca’s Pharmacovigilance 
process.  
8.1.5 WHO/ECOG p erformance status  
WHO/ECOG PS will be assessed at the times specified in the assessment schedules (see the 
SoAs) ba
sed on the following: 
0. Fully active; able to carry out all usual activities without restrictions
1. Restricted in strenuous activity, but ambulatory and able to carry out light work orwork of a 
 sedentary nature (eg, light housework or office work)
2. Amb ulato ry and capable of self -care, but unable to carry out any work activities; up
and about more than 50% of waking hours
3. Capable of only limited self-care; confined to bed or chair more than 50% of waking
hours
4. Com
pletely disabled; unable to carry out any self -care  and totally confined to bed or
chair
5. Dead
Any signi
ficant change from baseline or screening must be reported as an AE. 
8.1.6 Other safety assessments  
If new
 or worsening pulmonary symptoms (eg, dyspnea) or radiological abnormality suggestive 
of pneumoni
tis/ILD is observed, toxicity management as described in detail in the Dosing 
Modification and Toxicity Management Guidelines (see Annex 1) will be applied. The results of the full diagnostic workup (including high-resolution computed tomography [HRCT], blood and sputum culture, hematological parameters, etc) will be captured in the eCRF. It is strongly 
recommended to perform a full diagnostic workup, to e xclude alternative causes such as 
lymphangitic carcinomatosis, infection, allergy, cardiogenic edema, or pulmonary hemorrhage. 
In the presence of confirmatory HRCT scans where other causes of respiratory symptoms have 
been excluded, a diagnosis of pneumonitis (ILD) should be considered and the Dosing 
Modification and Toxicity Management Guidelines should be followed.  
Pneumonitis (ILD) investigation  
The following assessments, and additional assessments if required, will be performed to enhance 
the inv e
stiga tion and diagnosis of potential cases of pneumonitis. The results of the assessment 
will be collected.  
• Physical examination

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 60 −Signs and symptoms (cough, shortness of breath, and pyrexia, etc) including
auscultation for lung field will be assessed.
• Saturation  of peripheral oxygen
• Other items
−When pneumonitis (ILD) is suspected during study treatment, the following
marke
rs should be measured where possible:
oILD markers (KL -6, SP- D ) and β -D-glucan
oTumor markers: Particular tumor markers which are related todisease pr 
ogression.
oAdditional clinical chemistry: C -reacti ve protein, lactate
dehydrogenase
8.2 Efficacy assessments 
Efficacy of  durvalumab will be  assessed in terms of  overa ll response ra te (ORR) and DOR i n 
patients who unde rgo retreatment with dur valumab from  Cohort 2 if there is a sufficient  sample 
size of  retreated pa tients, ot herwise , only lis tings w ill be  provided.  Disease progression w ill be  
determined by  the Inve stigator following  RECIST v1.1;  only the  results o f assessments w ill be  
entered into the eCRF. The RECIST v1.1 guidelines for Investigator’s tumor assessments, 
including protocol-specific requirements, are summarized in Appendix C.  
8.2.1 Parent study assessments 
To acc
urately capture endpoints for this study, the following data elements must be transferred 
from the p
arent studies for analysis purposes. Minimal mandatory data elements will be entered 
into the EDC (eg, patient identification); the remainder will be retained in a separate database. 
This list may be updated or modified depending on the availability and required elements 
determined for the study endpoints and will be fully captured in the statistical analysis plan 
(SAP).   
• Parent study name, study code, site name, and site number
• Patient identification or linkage key, including connection to the IVRS of the parentstudy and t 
ransfer of old enrollment code (E- code)
• Date of randomization
• Demographics: including date of birth and sex
• HIV status

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 61 • Baseline disease information: date of cancer diagnosis, indication, and stage of disease
• All tumor assessment information, including: dates of scans (including baseline
compar
ison scan), results of each assessment (response, SD, p rogression)
• Study drug administration, including:
−Date of first administration of durvalumab and durvalumab combination treatment
−Date and last dose of durvalumab and durvalumab combination treatment
adminis
tration
• Ongoing safety events at the end of parent study, including SAEs or adverse events of
spec
ial interest (AESIs) while on treatment with durvalumab and/or durvalumab
combination therapy.
• Ongoing concomitant medications at the end of the parent study
• First subsequent anticancer therapy after durval umab dis continuation (Cohort 3 only)
• Last date of patient contact
• Contact information (patient, caregiver, physician) as allowed by regulation for eachcountry
8.2.2
 Survival assessments
Asse
ssments for survival must be made every 3 months (±2 weeks) beginning 90 days after the 
last dos
e of study drug. Survival information may be obtained via telephone contact with the 
patient or the patient’s family (or a prespecified preferred method of contact, as an alternative), 
or by contact with the patient’s current physician. The details of first subsequent anticancer 
therapy and overall best response after discontinuation of durvalumab treatment will be collected 
from the Investigator.  
In addition, patients on treatment or in survival follow -up will  be contacted followi ng the data 
cut-off (DCO) for the primary analysis and all subsequent survival analyses to provide complete 
survival data. These contacts should generally occur within 7 days of the DCO. 8.2.3 Clinical endpoint assessments  
Data for the  following  endpoint
 s will be  collected and  may be  evaluated as pa rt of the analysi s in 
the parent clinical studies from  which the  patients or iginated.  Survival data w ill be  collected in 
terms of  OS in a ll patients. E fficacy v ariables w ill be  collected in te rms o f ORR a nd DOR for  
patients in Cohort 2 who start retreatment according to clinical practice (so long as they satisfy 
eligibility criteria in Section 5.1). These endpoints are defined below:  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 62 • OS is defined as the time from date of randomization/enrollment in the parent clinical
study until the date of death by any cause (all cohorts).
• ORR is defined as the number (%) of patients with a confirmed response of completerespons 
e (CR) or partial response (PR) from the re -initiation of treatment with
durvalumab monotherapy (Cohort 2).
• DOR is defined as the time from first documented CR or PR until the time of firstdocum 
ented disease progression or death in the absence of disease progression
(Cohort 2).
Tumor assessments, performed by the Investigator according to standard practice, to determine ORR an
d DOR will be collected for patients in Cohorts 1 and 2 at least every 12  weeks while the 
patient is receiving treatment. Assessments should be performed as deemed medically 
appropriate by the Investigator, for the purpose of maintaining the safety and wellbeing of the 
patient. Investigator reported response will be collected and summarized.  
8.3 Collection of adverse events 
The Principal Investigator is r esponsible for ensuring  that all staff involved in the  study a re 
familiar with the content of this section. 
The definitions of an AE or SAE can be found in Appendix A. 
AEs will be reported by the patient (or, when appropriate, by a caregiver, surrogate, or the 
patient’s legally a uthorized re presentative).  
The Investigator and any designees are responsible for detecting, documenting, a nd recording 
events that meet the definition of an AE or SAE. For information on how to follow/up AEs, 
see Section 8.3.3.  
8.3.1 Metho d o f detecting AEs and SAEs  
Care will be taken not to introd uce bia s when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the patient is the preferred method to inquire about 
AE occurrences.  
8.3.2 Time period and frequency for collecting AE and SAE information 
AEs and  SAEs will be  collec ted from the  time o f the patient signing  the ICF unt il the  follow -up 
period  is completed (90  days  after the la st dose o f durvalumab). If an event that starts pos t the 
defined safety follow-up period noted above is considere d to be due t o a late onset toxicity to 
study drug, then it should be reported as an AE or SAE as applicable. Collection and reporting of 
AEs and SAEs after the final DCO is described  in Section 8.3.14. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 63 All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated 
in Appendix A. The Investigator will submit any updated SAE data to the Sponsor within 
24 hours of it being available. 
Investigators a re not  obligated to a ctively s eek A E or SAE in for mer study pa tients. H owever, if 
the Inve stigator  learns o f any  SAE, inc luding  a death,  at any t ime a fter a p atient’s last visit and 
he/she considers the event to be reasonably related to the study treatment or study participation, 
the Investigator should notif y the Sponsor. 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix A. 
8.3.3 Follow- up of  AEs and SAEs  
After the in itial AE/SAE re port, the Investigator  is re quired to pr oactively follow  each patient at 
subsequent visits/contacts. All SAEs/non-s erious AEs/AESIs (as defined in Section  8.3.13 and 
Appendix A) will be followed until resolution, stabilization, the event is otherwise explained, or 
the patient is los t to follow -up  
Any AEs that ar e unresolved at the patient’s last AE assessm ent or other assessment/visit as 
appropriate in the study are followe d up by the Investig ator fo r as long  as me dically in dicated 
(this may be beyond the 90 days after the last dose of durvalumab), but without further recording 
in the  CRF. A straZeneca re tains  the right to request additional inf ormation  for any patient with 
ongoing AE(s)/SAE(s) at the end of the study, if judged necessary. 
8.3.4 Adverse event d ata col lection  
The following  variables will be  collected fo r each A E: 
• AE (verbatim)
• The date when the AE started and stopped
• The maximum CTCAE grade reported
• Changes in CTCAE grade (report only t he m ax imum CTCAE grade for a calendar
day)
• Whether  the AE is serious or not
• Investigator causality rating against the IPs (yes or no)
• Action taken with regard to IPs
• Administration of treatment for the AE
• Outcome

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 64 In addition, the following variables will be collected for SAEs: 
• Date the AE met criteria for SAE
• Date the Investigator became aware of the SAE
• Seriousness criteria
• Date of hospitalization
• Date of discharge
• Probable cause of death
• Date of death
• Whethe r  an autopsy was performed
• Caus ality  assessment in relation to study procedure(s)
• Causality assessment in relation to other medication, as explained in Section  8.3.5
• Description of the SAE
The gr
ading scales found in the revised NCI CTCAE version 5.0 will be utilized for all events 
with an a
ssigned CTCAE grading. For those events without assigned CTCAE grades, the 
recommendation in the CTCAE criteria that converts mild, moderate, and severe events into 
CTCAE grades should be used. A copy of the CTCAE version 5.0 can be downloaded from the 
Cancer Therapy Evaluation Program website ( http://ctep.cancer.gov).  
8.3.5 Causality collection  
The Investigator w ill as sess causal relationship between IP and each AE, and  answer ‘yes’ or 
‘no’ to the question ‘Do you consider that there is a reasonable possibility that the event may 
have been caused by the IP?’ 
For SAEs, t he causal relationship w ill also be  assessed for other medication a nd study 
procedures and/or AZ Medical device. Note t hat for SAEs that could be associated with any 
study procedure the causal relationship is implied as ‘yes’. 
A guide to the interpretation of the causality question is found in Appendix A. 
8.3.6 Adverse events based on  signs and symptoms 
All AEs spontaneously reported by the patient or care provider or reported in response t o the 
open question from the study site staff: ‘Have you/the child had any health problems since the 
previous visit/you  were last as ked?’ , or reveale d by observation will be collected a nd recorded in 
the CRF. When collecting AEs, the recording of diagnoses is preferre d (when possible) to 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 65 recording a list of signs and symptoms. However, if a diagnosis is known and there are other 
signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or 
symptom wi ll be recorded separately.  
8.3.7 Adverse events based on examinations and tests  
The resu
lts from the c linical  study protocol mandated laboratory tests and vital signs will be 
summarized in the clinical study report (CSR). Deterioration as compared to baseline in  protocol 
mandated laboratory values and/or vital signs should therefore only be reported as AEs if they 
fulfill any of the SAE criteria or are the reason for discontinuation of treatment with the IP or are 
considered to be clinically relevant as judged by the investigator (which may include but not 
limited to consideration as to whether treatment or non -planned visits were required or other 
action was taken with the study treatment, e.g. dose adjustment or drug interruption). Clinically 
relevant deteriorat ions in non- mandated parameters should also be reported as AE(s).  
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign
 or symptom will be reported as an AE and the associated laboratory result/vital sign will 
be considered as additional information. Wherever possible the reporting Investigator uses the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value).  
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be repo
rted as an AE/SAE. 
Any new or aggravated clinically relevant abnormal medical finding at a physical examination as 
compared
 with the baseline assessment will be reported as an AE unless unequivocally related to 
the dise ase under study (DUS), see Sections 8.3.9  and 8.3.10. 
8.3.8 Hy’s law  
Cases w
here a patient shows elevations in liver biochemistry may require further evaluation and 
occurre
nces of AST or ALT ≥3 ×  ULN together with total bilirubin ≥2 ×  ULN may need to be 
reported as SAEs. Please refer to  Appendix B  for further instruction on cases of increases in liver 
biochem
istry and evaluation of HL or Potential Hy’s law. 
8.3.9 Disease un der study 
Symptoms of DUS are those which might be expected to occur as a direct result of the patient’s primar
y malignancy. Events which are unequivocally due to DUS should not be reported as an 
AE during the study unless they meet SAE criteria or lead to discontinuation of the IP. 
8.3.10 Disease progression  
Disease progression can be considered as a worsening of a patient’s condition attributable to the 
disease f
or which the IP is being studied. It may be an increase in the severity of the DUS and/or 
increases in the symptoms of the disease. The development of new, or progression of existing 
metastasis to the primary cancer under study  should be considered as disease progression and not 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 66 an AE. Events, which are unequivocally due to disease progression, should not be reported as an 
AE during the study. 
8.3.11 New cancers 
The dev
elopment of a new cancer should be regarded as an SAE. New primary cancers are those 
that are n
ot the primary reason for the administration of the IP, and have been identified after the 
patient’s inclusion in this study.  
8.3.12 Deaths  
A
ll deaths that occur during the study treatment period, or within the protocol- defined f ollow -up 
period after the administration of the last dose of study drug, must be reported as follows: 
• Death clearly resulting from disease progression should be reported to the Study
Monitor
/Physician at the next monitoring visit and should be documented in the eCRF
in the Statement of Death page. It should not be reported as an SAE.
• Where de ath is not due (or not clearly due) to progression of the DUS, the AE causing
the death must be reported to the Study Monitor/Physician as an SAE within 24 hours.
It should also be documented in the Statement of Death page in the eCRF. The report
should contain a comment regarding the co involvement of PD, if appropriate, andshould assign main and contributory causes of death.
• Deaths with an unknown cause should always be reported as an SAE. It should also bedocument
ed in the Statement of Death page in the eCRF. A post mortem may be
helpful in the assessment of the cause of death, and if performed,  a copy of the
post- mortem results should be forwarded to AstraZeneca Patient Safety or its
representative within the usual timeframes.
Deaths occurring after the protocol- defined  safety follow -up period after the administration of 
the last dose of study drug should be documented in the Statement of Death page. If the death occurred as a result of an event that started post the defined safety follow -up period, and the  
event is considered to be due to a late onset toxicity to study drug, then it should also be reported 
as an SAE.  
8.3.13 Adverse events of special interest  
An AE
SI is one of scientific and medical interest specific to understanding of the IP and may 
require
 close monitoring. An AESI may be serious or non-serious. The rapid reporting of AESIs 
allows ongoing surveillance of these events in order to characterize and understand them in 
association with the use of this IP.  
AESIs for durvalumab include but are not limited to events with a potential inflammatory or immune -medi 
ated mechanism and which may require more frequent monitoring and/or 
interventions such as steroids, immunosuppressants and/or hormone replacement therapy. These 
AESIs are being closely monitored in clinical studies with durvalumab monotherapy and 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 67 combination therapy. An imAE is defined as an AESI that is associated with drug exposure and 
is consistent with an immune-mediated MOA and where there is no clear alternate etiology. 
Serologic, immunologic, and histologic (biopsy) data, as appropriate, should be used to support 
an imAE diagnosis. Appropriate efforts should be made to rule out neoplastic, infectious, metabolic, toxin, or other etiologic causes of the imAE.  
If the Investigator has any questions in regard to an event being an imAE, the Investigator should 
promptly c
ontact the Study Physician. 
AESIs observed with durvalumab include: 
• Diarrhea/colitis and intestinal perforation
• Pneumonitis/ILD
• Endocrinopathies (ie, events of hypophysitis/hypopituitarism, adrenal insufficiency,
hyper-  a
nd hypothyroidism and type I DM)
• Hepatitis/transamina se increas es
• Nephritis/blood creatinine increases
• Pancreatitis/serum lipase and amylase increases
• Rash/dermatitis
• Myocardi tis
• Myositi s/polymyositis
• Neuropathy/neuromuscular toxicity (eg, Guillain- Barré an d myasthenia gravis)
• Other inflammatory responses that are rare/less frequent with a potentialimmune -m 
ediated etiology include, but are not limited to, pericarditis, sarcoidosis,
uveitis, and other events involving the eye, skin, hematological, and rheumatological
events.
In addition, infusion -related re actions and hypersensitivity/anaphylactic reactions with a different 
underlying pharmacological etiology are also considered AESIs. 
Further information on these risks (eg, presenting symptoms) can be found in the current version 
of the durv
alumab IB. More specific guidelines for their evaluation and treatment are described 
in detail in the Dosing Modification and Toxicity Management Guidelines (see Annex 1). These 
guidelines have been prepared by the Sponsor to assist the Investigator in the exerc ise of his/her 
clinical judgment in treating these types of toxicities. These guidelines apply to AEs considered causally related to the study drug/study regimen by the reporting Investigator. 

Cli nical St u d y Pr ot oc ol – v 4. 0  Astra Ze nec a 
D ur val u ma b- D 9 1 0 F C 0 0 0 0 1  
C O N FI D E N TI A L A N D P R O P RI E T A R Y  6 8  8. 3. 1 4  S afet y d at a t o be c ollecte d f oll o wi n g t he fi n al D C O of t he st u d y 
F or patie nts c o nti n ui n g t o recei ve d ur val u ma b treat me nt after fi nal D C O a n d data base cl os ure, 
A Es a n d S A Es will c o nti n ue t o be c ollecte d, b ut o nl y S A Es will be re p orte d. I n a d diti o n, it is 
rec o m me n de d t hat t he patie nts c o nti n ue t he sc he d ule d site visits a n d I n vesti gat ors m o nit or t he 
patie nt’s safet y la b orat or y res ults peri o dicall y d uri n g treat me nt wit h d ur val u ma b i n or der t o 
ma na ge A Es i n acc or da nce wit h t he d ur val u ma b D osi n g M o dificati o n a n d T o xicit y Ma na ge me nt 
G ui deli nes (see A n ne x 1). All data p ost t he fi nal D C O a n d data base cl os ure will be rec or de d i n 
t he patie nt n otes b ut, wit h t he e xce pti o n of S A Es ( w hic h will be re p orte d o n pa per), will n ot 
ot her wise be re p orte d f or t he p ur p oses of t his st u d y. 
All S A Es t hat occ ur i n patie nts still recei vi n g d ur val u m a b treat me nt ( a n d wit hi n t he 9 0 da ys 
f oll o wi n g  t he last d ose of d ur val u ma b treat me nt) p ost t he fi nal D C O a n d data base cl os ure m ust 
be re p orte d as detaile d i n Secti o n 8. 4. 1 . 
8. 4  S afet y re p orti n g a n d me dic al m a n a ge me nt  
8. 4. 1  Re p orti n g of seri o us a d verse e ve nts  
All S A Es m ust be re p orte d, w het her or n ot c o nsi dere d ca usall y relate d t o t he I P, or t o t he st u d y 
pr oce d ure (s). All S A Es will be rec or de d i n t he C R F. C ollecti o n a n d re p orti n g of S A Es after t he 
fi nal D C O  is descri be d i n Secti o n  8. 3. 1 4 . 
If a n y S A E occ urs i n t he c o urse of t he st u d y, t he n I n vesti gat ors or ot her site pers o n nel i nf or m t he 
a p pr o p riate Astra Ze neca re prese ntati ves wit hi n 1 da y (ie, i m me diatel y b ut n o l ater t h a n 
2 4 h o urs of w he n he or s he bec o mes a ware of it). 
T he desi g nate d Astra Ze neca re prese ntati ve w or ks wit h t he I n vesti gat or t o e ns ure t hat all t he 
nece ssa r y i nf or mati o n is pr o vi de d t o t he Astra Ze neca Patie nt Safet y data e ntr y site wit hi n 1  
c ale n d ar d a y  of i nitial recei pt f or fatal a n d life -t hreate ni n g e ve nts a n d wit hi n 5 c ale n d ar  d a ys 
of i nitial recei pt f or all ot her S A Es.  
F or fatal or life -t hrea te ni n g A Es w here i m p orta nt or rele va nt i nf or mati o n is missi n g, acti ve 
f oll o w - u p is u n derta ke n i m me diatel y. I n vesti gat ors or ot her site pers o n nel i nf or m Astra Ze neca 
re prese ntati ves of a n y f oll o w- u p i nf or mati o n o n a pre vi o usl y re p orte d S A E wit hi n 1 cale n dar da y 
(ie,  i m me diatel y b ut n o l ater t h a n 2 4 h o urs of w he n he or s he bec o mes a ware of it). 
T he f oll o wi n g e- mail a d dre ss s h o ul d be use d f or all ot her cli nical st u d y case re p orts , a n d f or 
re p orti n g of S A Es after t he fi nal D C O;  
As a bac k - u p, i n t he e ve nt of a sec ure e- mail li n k is u na vaila ble e. g. d ue t o net w or k iss ues, t he 
f oll o w i n g fa x n u m bers s h o ul d be use d.  
Fa x n u m bers: 
•P P D 
P P D 
Cli nical St u d y Pr ot oc ol – v 4. 0  Astra Ze nec a 
D ur val u ma b- D 9 1 0 F C 0 0 0 0 1  
C O N FI D E N TI A L A N D P R O P RI E T A R Y  6 9  F or f urt her g ui da nce o n t he defi niti o n of a S A E, see  A p pe n di x A  of t he Cli nical St u d y Pr ot oc ol. 
8. 4. 2  Pre g n a nc y 
All pre g na ncies a n d o utc o mes of pre g na nc y s h o ul d be re p orte d t o Astra Ze neca e xce pt f or:  
• If t he pre g na nc y is disc o vere d bef ore t he st u d y patie nt has recei ve d a n y st u d y dr u g 
If a  pre g na nc y is re p ort e d, t he In vesti gat or sh o ul d i nf or m the Sp o ns or wit hi n 2 4 h o urs of 
lear ni n g of t he pr e g na nc y. 
A b n or mal pre g na nc y o utc o mes (eg, s p o nta ne o us ab orti o n, fetal de at h, still birt h, c o n ge nital 
a n o malies,  e ct o pic pre g na nc y)  a re c o nsi dere d  S A Es.  
8. 4. 2. 1  M at er n al  e x p os ure  
If a pa tie nt bec o mes pre g na nt d ur i n g t he co urse of the stu d y, t he IP sh o ul d be di sc o nti n ue d 
i m me diatel y.  
Pre g na nc y itself is n ot re gar de d as a n AE u nl ess there is a sus pici o n t hat t he IP u n de r st u d y ma y 
ha ve i nterfere d  w it h  t he  effecti ve nes s of a co ntrace pti ve me dicati o n. C o n ge nital 
a b n or malities/ birt h defects an d s p o nta ne o us miscarria ges sh o ul d be re p orte d a n d ha n dle d as 
S A Es. Electi ve ab orti o ns wit h o ut co m plicati o ns s h o ul d n ot be ha n dle d as AEs. T he o ut c o me of 
all  p re g na ncies (s p o nta ne o us m iscarria ge, electi ve ter mi nati o n, ect o pic pr e g na nc y, n or mal bi rt h 
or co n ge nital ab n or malit y) sh o ul d be foll o we d u p an d d oc u me nte d e ve n if t he pa tie nt was 
disc o nti n ue d fr o m t he st u d y. 
If an y pre g na nc y occ urs i n t he co urse of the st u d y, t he n t he I n vesti gat or  or  ot her site  p ers o n nel 
i nf or ms  t h e a p pr o priate  Astra Ze neca  re prese ntati ves  w it hi n  1  da y (ie , i m me diatel y  b ut n o l ater 
t h a n 2 4  h o u rs  of  w he n  h e or  s he  bec o mes a war e of  i t).  
T he desi g nate d  A stra Ze neca re prese ntati ve w or ks wit h  t he  I n vesti gat or  t o  e ns ure t hat all rele va nt 
i nf or mati o n  is  p r o vi de d  t o t h e A stra Ze neca  P atie nt Safet y  d ata  e ntr y  s ite  w it hi n  1 o r 5  c ale n dar 
da ys f or  S A Es (see Secti o n  8. 4. 1 ) a n d wit hi n 3 0 da ys f or all ot her pre g na ncies. 
T he sa m e ti meli nes a p pl y  w he n  o ut c o me i nf or mati o n  is a vaila ble.  
8. 4. 2. 2  P ater n al  e x p os ure  
Male pa tie nts sh o ul d refrai n fr o m fat heri n g a c hil d or d o na ti n g s per m d u ri n g t he st u d y an d f or 
1 8 0 da ys after  t he  last  d ose of  d ur val u ma b  +  tre meli m u ma b  c o m bi nati o n  t he ra p y  o r 9 0  da ys after  
t he last d os e of d ur val u ma b m o n ot hera p y, w hic he ver is t he l o n ger ti me peri o d.  P P D 
Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 70 Pregnancy of the patient’s partner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or 
congenital abnormality) occurring from the date of the first dose until 180 days after the last dose 
of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period should, if possible, be followed 
up and documented. 
Where a report of pregnancy is received, prior to obtaining information about the pregnancy, the 
Investi
gator must obtain the consent of the  patient’s partner. Therefore, the local study team 
should adopt the generic ICF template in line with local procedures and submit it to the relevant Ethics Committees (ECs)/Institutional Review Boards (IRBs) prior to use.  
Patients who are permanently discontinued from further receipt of IP, regardless of the reason, 
will be
 identified as having permanently discontinued treatment and will enter follow- up (see the 
SoAs).  
8.4.3 Overdose  
8.4.3.1 Durv
alumab 
Use of
 durvalumab in doses in excess of that specified in the protocol is considered to be an 
overdose. T
here is currently no specific treatment in the event of an overdose of durvalumab, and 
possible symptoms of overdose are not established.  
• An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the
rele
vant AE modules in the CRF and on the Overdose CRF module.
• An overdose without associated symptoms is only reported on the Overdose CRFmodule.
I
f an overdose on an AstraZeneca study drug occurs in the co urse of the study, the n the 
Investigator or  other site pe rsonnel infor m appropriate AstraZeneca representatives im mediately,  
or no later than 24 hours of  when h e or she becomes awar e of it. 
The designated A straZeneca representative works with the  Investigator to ensure that all relevant 
information is provided to the AstraZeneca Patient Safety data entry site. 
For overdoses associated with an SAE, the standard reporting timelines apply, see Section 8.3.2.  
For other overdoses , reporti ng must occur within 30 days. 
8.4.4 Management of durvalumab- related toxi cities  
The following general guidance s hould be  followed for  the management  of toxicities. 
• Treat each of the toxicities with maximum supportive care (including holding the
agent  s
uspected of causing the toxicity if required).

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 71 • If the symptoms promptly resolve with supportive care, consideration should be given
to continue the same dose of the assigned IP along with appropriate continuing
supportive care. If medically appropriate, dose modifications are permitted.
• All dose modifications should be documented with clear reasoning and documentation
of the a
pproach taken.
All toxicities will be graded according to NCI CTCAE, version 5.0 (see Annex 1).  
8.4.4.1 Specific toxicity management and dose modification information – Durvalumab 
Compre
hensive toxicity management guidelines (TMGs) have been developed to assist 
invest
igators with the recognition and management of toxicities associated with use of the 
immune checkpoint inhibitors. Given the similar underlying mechanism of toxicities observed 
with these 2 compounds, these TMGs are applicable to the management of patients receiving 
either drug as monotherapy or both drugs in combination. Additionally, these guidelines are 
applicable when either drug is used alone or both drugs are used in combination and, also other anticancer drugs (ie, antineoplastic chemotherapy, targeted agents) are administered concurrently 
or sequentially as part of a protocol-specific treatment regimen. The TMGs provide information 
for the management of immune -mediated  reactions, infusion -related reactions, and non-immune-
mediated reactions that may be observed with checkpoint inhibitor monotherapy or combination 
checkpoint inhibitor regimens, with specific instructions for checkpoint inhibitor- specific dose 
modificatio ns (including discontinuation) and treatment interventions. Investigators are advised 
however to use local practice guidelines and consult local references for the management of toxicities observed with other anticancer treatment.  
The most current version of the TMGs is provided to the investigative site as an Annex to 
Protoc ol
 document entitled, “Dosing Modification and Toxicity Management Guidelines for 
Immune -Mediated, Infusion-Related, and Non-Immune–Mediated Reactions (MEDI4736 
Monotherapy or Combinati on Therapy with Tremelimumab or Tremelimumab Monotherapy),” 
and is maintained within the Site Master File. In addition, a current version of TMGs is available 
through the following link:  https://tmg.azirae.com.  Please contact the clinical study associate for 
infor
mation on how to gain access to this website. 
Patients should be thoroughly evaluated, and appropriate efforts should be made to rule out neoplast
ic, infectious, metabolic, toxin, or other etiologic causes of the imAE. Serologic, 
immunologic, and histologic (biopsy) data, as appropriate, should be used to support an imAE 
diagnosis. In the absence of a clear alternative etiology, events should be considered potentially 
immune -related. In addition, there are certain circumstances in which durvalumab should be 
permanently discontinued (see Section 7.1 o f this protocol and the TMGs). Following the first 
dose of I
P, subsequent administration of durvalumab can be modified based on toxicities 
observed as described in the Dosing Modification and Toxicity Management Guidelines (see 
Annex 1). These guidelines have been prepared by the Sponsor to assist the Investi gator in the 
exercise of his/her clinical judgment in treating these types of toxicities. These guidelines apply 
to AEs considered causally related to durvalumab monotherapy and the durvalumab combination 
regimen by the reporting Investigator. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 72 8.5 Pharmacokine tics 
Not applicable. 
8.6 Pharmacodynamics 
Not applicable. 
8.7 Genetics  
Not applicable. 
8.8 Biomarkers  
Not applicable. 
9. STATISTICAL CONSIDERATIONS
9.1 Sample siz e determination
The number of patients enrolled in this study will be determined by the number of patients who 
received durvalumab and/or durvalumab in combination with any other approved or 
investigational anticancer agents in original trials, and who wish to participate and who meet the eligibility criteria. The study will enroll up to 600 patients a nd the number of patients may 
increase as new parent studies are included into this long -term safety and efficacy study.  
9.2 Populations for analyses 
The study population used for statistical analyses in this study is described in Table 11 . Full 
detail
s will be provided in the SAP. 
Table 11 Popula tion for statistical analyses  
Analysis sets  Description  
Full analysis set  Patients enrolled in the study.  
Safety analysis set  Patients who received at least 1 dose of durvalumab on this study or 
enrolle
d on this study within 90 days of the last dose of durvalumab or 
durvalumab combination on the respective parent clinical study.  
Response evaluable analysis set
a Patients who are retreated with durvalumab in Cohort 2. 
a.To be performed  if there is  a sufficient sample size of retreated patients ; otherwise, only lis tings will be
provided.

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 73 9.3 Statistical analyses  
There are no statistical methods that will be employed to test a specific hypothesis. A 
comprehensive SAP will describe the patient populations to be included in the analyses, and 
procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoi nts. Any  deviations from this 
plan will  be reported in  the CSR. 
9.3.1 Safety analyses 
Safety
 data will be summarized according to the treatment receive d for th e safety analysis set ( all 
patients who received at least 1 dose of durvalumab either as continuation of study treatment or 
retreatment in this study, and inclusive of patients who received the last dose of durvalumab or durvalumab combination from the parent clinical study within 90 days of enrollment [all 
cohorts]). AEs, vital signs, and laboratory safety assessments (clinical chemistry, hematology 
and thyroid- stimulating hormone [reflex free triiodothyronine or free thyroxine]) will be listed 
individually by patient. The number of patients experiencing each AE will be summarized by 
study cohort and CTCAE grade (v5.0) (see Annex 1). 
9.3.2 Efficacy analyses 
One secon
dary objective is to assess the efficacy of durvalumab in terms of ORR and DOR for 
retreated
 patients. The analysis set for ORR and DOR will be based on the patients who undergo 
retreatment with durvalumab in Cohort 2. Data will be summarized by tumor type if there is 
sufficient sample size in each tumor type. ORR will be estimated with a 95% CI using the exact 
probability meth od. The median DOR and its 95% CI will be estimated using the Kaplan -Meier 
method. ORR and DOR will be assessed in the response evaluable analysis set. If there are not 
sufficient counts of retreated patients to conduct the efficacy analysis, then only listings will be 
provided. Further detail will be provided in the SAP.  
A listing of OS data will be provided for full analysis set. 
In addition, survival and tumor efficacy data in this study may be combined with the parent study 
data fo r in
tegrated analysis . In the integrated analysis, OS will be described using the 
Kaplan -Meier method. 
Efficacy of durvalumab will be assessed in terms of ORR, DOR, and OS as defined in Section  
9.3.3. 
9.3.3 Endpoint measures for analyses  
9.3.3.1 Calc
ulation or derivation of safety variables 
Safety
 and tolerability will be assessed in terms of AEs (including SAEs), deaths, laboratory 
data, vit
al signs, and exposure (ie, durvalumab monotherapy or combination therapy). These will 
be collected for all patients. “On treatment” will be defined as assessments between date of start dose and 90 days following discontinuation of IP (ie, the last dose of durvalumab in combination 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 74 with any other approve d or investigational anticancer agents or durvalumab monotherapy). For 
AEs, on tre atment (or  treatment- emergent AEs) will be de fined a s any AEs tha t started a fter 
dosing or prior to dosi ng and which worsens following exposure to the treatment. For the change 
from baseline summaries for vital signs, laboratory data, and physical examinations , the baseline 
value  will be the l atest result obtained pr ior to th e start of study  treatment, or  the date of 
enrollment if the  patient is not  to receive  study treatment (Cohort 3). The denominator in vital 
signs data should include only those patients with recorded data. 
AEs observed up until 90 days following discontinuation of durvalumab will be used for the 
reporting of the AE summar y tables. Any AEs in this period tha t occur af ter a patient has 
received subsequent anticancer therapy will be flagged. Reporting and collection of late onset 
toxicity after the 90-day period is described in Section 8.3.2. 
More de tails w ill be  provided in the  SAP. 
9.3.3.2 Investigator RECIST 1.1-b ased assessments 
Tumor assessments will be conducted by the Investigator using RECIST v1.1 (Appendix C).  
9.3.3.3 Objective response rate 
ORR i s defined as the number ( %) o f patients with a confirmed respons e of CR or PR. D ata 
obtained up until progression, or the last evaluable assessment in the absence of progression, will 
be include d in the assessment of ORR. Patients who go off treatment without progression, 
receive a subsequent therapy, and then res pond will not b e included as responders in the ORR.  
9.3.3.4 Duration  of resp onse 
DOR i s defined as the  time from the date of first documented response (which is subsequently 
confirmed) until the first da te of progression  or death in the  absence of d isease progression. D OR 
will not b e define d for patients who do not have documented response. 
9.3.3.5 Overall survival 
OS is de fined a s the time from  date o f randomization/enrollment in th e parent clinical study  until 
the date of death by any cause.  
9.4 Interim analyses 
There are 5 interim analyses planned for this study, anticipated to occur annually starting 1 year 
after the first patient is enrolled. No formal statistical adjustments will be made for these interim 
looks and additional analyses may be performed for the purpose of better characterizing the 
safety of these patients with long -term follow -up. The SAP will describe  the planned interim 
analyses in greater detail.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 75 9.4.1 Data monitoring committee  
Review of safety data will be conducted in accordance with AstraZeneca’s Pharmacovigilance 
process (S
ection  8.1).  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 76 10. REFERENCES
FDA Guidance for Industry (issued July 2009) ‘Drug- induced liver injury: Premarketing clinical 
evaluation’ 
Alexandrov et al 2013 
Alexandrov LB, Nik- Zainal S , Wedge DC, Aparicio SAJR, Behjati S, Blankin AV, et al. 
Signatures of mutational processes in human cancer. Nature 2013;500:415-21. 
Brahmer et al 2012 
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 
antibody in patients with advanced cance r. N Engl J Med 2012;366(26) :2455-65. 
Dunn et  al 2004 
Dunn GP, O
ld LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 
2004;22:329-60. 
F
airman et al 2014 
Fairman D, Narwal R, Liang M, Robbins PB, Schneider A, Chavez C, et al. Pharmacokinetics of 
durvalum
ab, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid 
tumors. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts;32(5s): (suppl; abstr 2602).  
Forde et al 2014 
Forde PM, Kelly RJ, Brahmer JR. New strategies in l ung ca ncer: translating immunotherapy  
into clinical practice. Clin Cancer Res 2014;20(5):1067-73. 
Hirano et al 2005 
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and 
PD-1 by monoclona
l antibodies potentiates cancer ther apeutic immunity. Cancer Res 
2005;65(3):1089-96. 
Hodi et al 2010  
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanan JB, et al. Improved 
surviva
l with ipilimumab in patients with metastatic melanoma [published erratum appears in  
N Engl J Med 2010;363(13):1290]. N Engl J Med 2010;363(8):711-23. 
Iwai  et al 2002 
Iwa
i Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor 
cells
 in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. 
Proc Natl Ac ad Sci USA 2002;99:12293-7. 
Keir et al 2008  
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and its  ligands in tolerance and immunity. 
Annu Rev Immunol 2008;26:677-704. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 77 Narwal et al 2013 
Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investi
gational anti- interferon alpha monoclonal antibody, in systemic lupus erythematosus. Clin 
Pharmacokinet 2013;52:1017-27. 
Ng et al 2006 
Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer pati
ents based on population pharmacokinetic analysis. Pharm Res 2006;23(6):1275–84. 
Okazaki and Honjo 2007 PD-1 and PD- 1 ligan
 ds: from discovery to clinical application. Int Immunol 2007;19(7) :813-24. 
Okudaira et al 2009 Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, et al. Blockade of B7- H1 
or B7 -DC 
 induces an antitumor effect in a mouse pancreatic cancer model. Int J Oncol 
2009;35(4):741-9. 
Pardoll 2012 
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 
P
owles et al 2014 
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti- PD-L1) 
treatme
nt leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558 -62. 
Qin et al 2016  
Mechanisms of i mmune e vasion and current status of checkpoint inhibitors in non- small cell 
lung cancer. Cancer Med 2016;9:2169–70. 
Rizvi  et al 2015  
Riz
vi N, Brahmer J, Ou S- H, Seg al NH, Khleif SN, Hwu WJ. Safety and clinical activity of 
MEDI4736, an anti- programmed cell death -ligand -1 (PD -L1) antibody, in patients with non-
small cell lung cancer (NSCLC). J Clin Oncol 2015;33:Abstract 8032. Santini 2018  
Fernando C. Santini. Safety and Efficacy of Re- treatin
 g with Immunotherapy after Immune -
Related Adverse Events in Patient s with NSCLC. Cancer Immunology Research 6(9) September 
2018. 
Segal et al 2015 
Segal NH, Ou S -HI, Ba lmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and 
efficacy of MEDI4736, an anti- PD-L1 antibody, in patients from a squamous cell carcinoma of 
the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015;33:Abstract 3011. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 78 Stewart  et al 2015 
Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and 
charac
terization of MEDI4736, an antagonistic anti- PD-L1 monoclonal antibody. Cancer 
Immunol Res 2015;3(9):1052-62. 
Topalian et al 2012 
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity,
 and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med 2012;366:2443-
54. 
Wang  et al 2009 
Wang D
D, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing 
of monoclon
al antibodies in adult clinical trials. J Clin Pharmacol 2009;49(9):1012–24. 
Zhang et al 2008 
Zhang C, Wu S, Xue X, Li M, Qin X, Li W, et al. Antitumor immunotherapy by blockade of the PD-1/PD -L1 pa 
thway with recombinant human PD-1-IgV. Cytotherapy 2008;10(7):711-9. 
Zhang et  al 2012 
Zhang S, S
hi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing of 
theraIt pe
utic peptides and proteins in adults. J Clin Pharmacol 2012;52(1):18–28. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 79 11. SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
11.1 Study manageme nt 
This study will be performed by AstraZeneca’s representative with the guidance, input, review 
and approval of Astr aZeneca, including development of materials, recruitment, training and 
management of sites, EDC and data management and analysis.  
11.1.1 Data entry/electronic data capture 
All data
 will be collected and entered directly into the EDC system. All participating sites will 
have acc
ess to the data entered regarding the individual site its own enrolled patients. All sites 
will be fully trained on using the on -line data capture system, including eCRF completion 
guidelines and help files. Sites will be r esponsible for entering extracted patient data into a 
secure internet -based EDC registry database via the eCRF. Investigators and site personnel will 
be able to access their account with a username and password. All eCRFs should be completed 
by designated, trained personnel or the study coordinator, as appropriate. In most cases, the 
eCRF should be reviewed, electronically signed, and dated by the Principal Investigator. All 
changes or corrections to eCRFs are documented in an audit trail and an adequate ex planation is 
required. 
11.1.2 Source  do cuments  
In most cases, the source documents are contained in the patient’s medical record and data 
collecte
d on the CRFs must match the data in the medical records.  In some cases, the CRF, or 
part of the CRF, may also serve as source documents. In these cases, a document should be available at the Investigator’s site and clearly identifying those data that will be recorded in the CRF, and for which the CRF will stand as the source document. All original source 
documentation is expected to be stored at the site for the longest possible time required by local 
applicable regulations.  
11.1.3 File re
 tention and archiving  
To enable evaluations and/or audits from regulatory authorities or AstraZeneca, the Investigator 
agrees to
 keep record s, including the identity of all participating patients, all original signed 
ICFs, copies of all CRFs, SAE forms, source documents and adequate documentation of relevant 
correspondence (eg, letters, meeting minutes, telephone calls reports). The records sh ould be 
retained by the Investigator according to local regulations, or as specified in the study contract, 
whichever is longer.  
Each site will receive a study site file at study initiation which contains all documents necessary for the 
conduct of the registry and is updated throughout the study. This file must be available for 
review in the event the site is selected for monitoring, audits, or inspections and must be safely 
archived for at least 5 years after the completing participation in the study. Docu ments to be 
archived include the patient enrollment log and the signed ICF. In the event that archiving of the 
file is no longer possible at the site, the site will be instructed to notify AstraZeneca.  

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 80 11.1.4 Quality assurance and monitoring  
A study monitoring pl an, incl uding for -cause monitoring, that is appropriate for the study design 
will be developed and implemented.  
During the site initiation visit (performed remotely with the exception of sites in Japan), the 
monitor
 will provide training on the conduct of the study to the Investigator, co- Investigator(s), 
and all site staff involved in the study. In order to ensure the integrity of the data, sites will be monitored. Remote s ite monitoring will be performed by AstraZeneca’s representative to 
examine compliance with the protocol and adherence to the data collection procedures, to assess 
the accuracy and completeness of submitted clinical data, and to verify that records and 
documents are being properly maintained for the duration of the study. The monitor wil l perform 
source data verification by review of original patient records.  
The monitor will close out each site (performed remotely with the exception of sites in Japan) after the  
last patient’s final follow -up assessment is completed, all data have been entered and all 
outstanding monitoring issues have been resolved or addressed. All monitoring procedures and 
frequency of monitoring visits will be described in a monitoring plan. Monitor contact details for 
each participating site will be maintained in the Investigator Site File.  
Representatives of AstraZeneca’s quality assurance unit/monitoring team and competent 
regulato
ry authorities must be permitted to inspect all study -related documents and other 
materials at the site, including the Investigator Site F ile, the completed eCRFs and the patients’ 
original medical records. Audits may be conducted at any time during or after the study to ensure the validity and integrity of the study data. 
11.1.5 Data management 
A data m
anagement plan will be created before data co llection b egins and will describe all 
functions, processes, and specifications for data collection, cleaning and validation. The eCRFs 
will include programmable edits to obtain immediate feedback if data are missing, out of range, illogical or potentially erroneous. Concurrent manual data review will be performed based on 
parameters dictated by the plan. Ad hoc queries will be generated within the EDC system and 
followed up for resolution.  
High data quality standards will be maintained, and processes and p rocedure
 s utilized to 
repeatedly ensure that the data are as clean and accurate as possible when presented for analysis. 
Data quality will be enhanced through a series of programmed data quality checks that automatically detect out of range or anomalous data.  
11.1.6 Changes to the protocol 
Changes
 to the protocol will be documented in written protocol amendments. Major (ie, 
substa
ntial, significant) amendments will usually require submission to the relevant IRB/IECs for 
approval or favorable opinion. In such cases, the amendment will be implemented only after 
approval or favorable opinion has been obtained. 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 81 Minor (non-substantial) protocol amendments, including administrative changes, will be filed by 
at each participating site and will be submitted to the relevant IRB/IEC or regulatory authorities 
where required by pertinent regulations. Any amendment that could have an impact on the 
patient’s agreement to participate in the study requires the patient’s informed consent prior to continued participation in the study. 
11.1.7 Publication policy  
The re
sults of this study may be published or presented at scientific meetings. If this is foreseen, 
the Inves
tigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to pr otect proprietary information and to provide comments.  
The Sponsor will comply with the requirements for publication of study results. In accordance 
with stan
dard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Jo
urnal  Editors authorship requirements. 
12. ETHICAL AND REGULATORY CONSIDERATIONS
12.1 Guiding principles
To ensure the quality and integrity of research, this study will be conducted under the guidelines 
good pharmacoepidemiology practices issued by the International Society for Pharmacoepidemiology, the Declaration of Helsinki and its amendments, and any applicable 
national guidelines. 
The study will be conducted in compliance with the US FDA Title 21 Code of Federal 
Regulat
ions Part 50 – Protection of Human Patients and/or Part 56 –IRB; the International 
Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guidelines (15 December 2016) as they apply to non- interventional studies; the Declaration of Helsinki and 
its amendments; and the Health Insurance Por tability and Accountability Act of 1996. 
12.2 Required documents 
Prior to the enrollment of any patients in the study, the following documents must be provided by the site to the Sponsor (or their designee): 
• Copy of the IRB/IEC approval letter for the protocol and informed consent (all written
inform 
ation provided to the patient must be approved by the IRB/IEC)
• Copy of the IRB/IEC-approved informed consent document to be used
• Copy of the protocol sign-off page signed by the Investigator

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 82 • Fully executed s ite agreement
12.3 Financial disclosure  
Investigators and sub- investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statemen ts to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
12.4 Patient information and informed consent 
An ICF must b e signed by the patient (or the patient’s legally authorized representative) before 
his or her participation in the study. The medical file for each patient should document the informed consent process and that written informed consent was obtained prior to participation 
in the study. A copy of each signed ICF must be provided to the patient or the patient’s legally 
authorized representative. If applicable, it will be provided in a certified translation of the local language. All signed and dated ICFs must remain in each patient’s study file and must be 
available for verification by study monitors at any time.  
The ICF should be revised whenever there are changes to procedures outlined in the informed consent or
 when new information becomes available that may affect the willingness of the 
patient to participate. For any updated or revised ICFs, the medical file for each patient should document the informed consent process and that written informed consent was obtained for the updated/revised ICF for continued participation in the study. 
12.5 Patient confidentiality  
In order to maintain patient confidentiality, each patient will be assigned a unique patient identifier upon study enrollment. This patient identifier will be used in place of patient name for 
the purpose of data analysis and reporting. Medical record number or other local reference 
identifiers are not collected as part of the database. All parties will ensure protection of patient 
personal data and will not include patient names on any study forms, reports, publications, or in 
any other disclosures, except where required by law. In accordance with local regulations in each 
of the registry countries, patients will be informed about data handling procedures and asked for their consent. Data protection and privacy regulations will be observed in capturing, forwarding, 
processing, and storing patient data. Every effort will be made to protect participant 
confidentiality according to the Regulation (EU) 2016/679 (of the European Parliament and of 
the Council of 27 April 2016 on the protection of natural persons with regard to the processing of 
personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)), and refer to the European Commission “Standard Contractual Clauses” with respect to data transfers to Non -EU countries where appropriate.  
The database will be housed at the AstraZeneca’s representative in a physically and logically secure com p
uter system maintained by AstraZeneca’s representative in accordance with a 
written security policy. The system meets approved established standards for the security of 

Clinical Study Protocol – v4.0 AstraZeneca 
Durvalumab- D910FC00001  
CONFIDENTIAL AND PROPRIETARY 83 health information and is validated. The system also meets the standards of the ICH GCP E6 
guideline (revision 2) regarding electronic study data handling and is available for audit upon 
request. Patient confidentiality will be strictly maintained.   
12.6 Independent ethics committee (IEC)/institutional review board (IRB) 
Consistent with local regulations and prior to enrollment of patients at a given site , the study 
protocol will be submitted together with its associated documents (eg, ICF) to the responsible 
IRB/IEC for its review. Patient enrollment will not start at any site before the Client has obtained written confirmation of a favorable opinion/appr oval from the relevant central or local IRB/IEC. 
The IRB/IEC will be asked to provide documentation of the date of the meeting at which the favorable opinion/approval was given that clearly identifies the study, the protocol version, and the ICF version re viewed.  
Before implementation of any substantial changes to the protocol, protocol amendments will also be sub
mitted to the relevant IRB/IEC in a manner consistent with local regulations. Pertinent 
safety information will be submitted to the relevant IECs during the course of the study in 
accordance with local regulations and requirements. It is the responsibility of the Investigator to 
have prospective approval of the study protocol, protocol amendments , and ICF, and other 
relevant documents, if applicable , from their local IRB/IEC and provide documentation of 
approval to AstraZeneca’s representative. All correspondence with the IRB/IEC should be retained in the Investigator file.  
Should the study be terminated early for any unanticipated reason, the Inves tigator wi
 ll be 
responsible for informing the IRB/IEC of the early termination.  
